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1. Introduction 
1.1. Atherosclerosis  
Atherosclerosis is a progressive and chronic disease of the arterial blood vessels [1, 2]. An 
initial change in endothelial cells and subsequent inflammatory processes lead to formation 
of atheromatous plaques and arterial remodelling [1, 3-6]. The main consequences of 
atherosclerosis are myocardial infarction, stroke, peripheral artery disease and aortic 
aneurysm [2, 7]. It constitutes the major cause of death in western world [8, 9]. 
Atherosclerotic lesions pass through different stages of development and can be classified 
with the help of the American Heart Association (AHA) classification scheme.  
 
 
Figure 1.1:1 AHA Classification: Terms used for atherosclerotic lesions in histological classifications (taken 
from [10]). Flow diagram in center column indicates pathways in evolution and progression of human 
atherosclerotic lesions indicated in roman numerals. The left flow diagram defines the different stages of 
atherosclerosis. Arrows indicate the possible direction of changes in between the stages. 
Risk factors for the development of atherosclerotic vascular disease include modifiable and 
non-modifiable factors [2]. Modifiable risk factors like dyslipidemia, cigarette smoking, 
hypertension and diabetes are well known [11, 12]. Several studies display smoking and 
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diabetes as the strongest among these “traditional” risk factors [13-15]. Recent studies also 
describe hypertension as a important risk factor leading to increased arterial wall tension, 
altered endothelial function by angiotensin II and disturbed repair process [1].  Regarding 
dyslipidemia, elevated triglyceride, decreased high density lipoprotein (HDL) or increased 
low density lipoprotein (LDL) level is associated with a high risk of atherosclerosis [1, 16-
18].  
The current therapy regimes are based on these risk factors, including lifestyle changes and 
risk factor modification. The latter is mainly achieved by the pharmacotherapy of 
hypertension and dyslipidemia [19]. Lipid lowering agents and in particular statins have 
proven beneficial in several large studies [20-23]. The Heart Protection Study, for example, 
showed a reduction of risk of adverse cardiovascular events and death in patients with 
coronary and non-coronary atherosclerosis by about 25 % [20]. Besides lowering LDL and 
C-reactive protein (CRP) level, statin therapy also seems to exert an anti-inflammatory [24, 
25] and plaque stabilization effect [26, 27]. The therapy of hypertension also reduces the risk 
of adverse cardiovascular outcomes [28]. So far, there is no proof of positive effects on 
inflammation and arterial remodeling, but  following the CAMELOT study, 
antihypertensive therapy with either amlodipine of enalapril significantly lowered 
progression of coronary atherosclerosis [29]. The use of antiplatelet drugs within the 
therapy reduces the risk of cardiovascular events in patients with atherosclerosis [19].  
Non-modifiable risk factors for atherosclerosis include age, male gender and family history 
[11]. Showing a strong heritable component, various epidemiological studies dealt with the 
identification of the genetic background and found genetic polymorphisms in at least 100 
genes related to the pathogenesis of atherosclerosis. Further research is needed to 
understand the exact linkage and to identify new targets for therapeutic intervention among 
these [12, 30].  
Looking closer into molecular mechanisms of atherogenesis, a qualitative change in the 
endothelial cells is observed initially. Endothelial cells express adhesion molecules that bind 
leukocytes to their surfaces (Figure 1.1:2 and Figure 1.1:3 B) when triggered through 
irritative stimuli [1, 4-6, 12]. These stimuli can include dyslipidemia, hypertension or pro-
inflammatory mediators. In the arterial wall, the assimilated monocytes differentiate into 
macrophages that by inclosing lipoprotein particles turn into foam cells (Figure 1.1:2 and 
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Figure 1.1:3 B). Entry of cholesterol-containing low-density lipoprotein (LDL) in the artery 
wall is facilitated by the changes in the endothelial permeability [1, 4, 5]. The endothelial 
dysfunction seems to be integral to the development and progression of the disease [12]. 
Modified lipid particles undergo endocytosis by monocyte-derived macrophages and this 
leads to intracellular cholesterol accumulation. Hence, dyslipidemia and inflammation are 
both major factors in the development of atheromatous plaques and intersect each other 
throughout all stages of atherosclerosis [1, 4-6]. 
 
 
Figure 1.1:2 Role of LDL particles in the development of atherosclerotic lesions (adapted from [5]). LDL 
particles penetrate and accumulate in the intima of the arterial wall. Modified LDL particles can induce 
expression of adhesion molecules and endothelial cell activation. Macrophages internalize LDL particles 
with the help of scavenger receptors and turn into foam cells. Oxidized lipids may also modulate SMC 
function, like increasing of the adhesion to macrophages and foam cells in plaques. 
Atheroma formation also includes the migration of smooth muscle cells (SMC) from the 
tunica media into the tunica intima of the arterial wall (Figure 1.1:3 C). Unlike in most 
animal, the human intima already features resident SMCs [1]. The SMCs of the media 
undergo a phenotypic change into a migratory and secretory cell that migrate into the 
tunica intima and proliferates due to mediators such as growth factors and cytokines [1, 12]. 
The SMCs in the intima form a fibrous cap covering the plaque overlaying a collection of 
foam cells. The inefficient clearance of dead cells lead to accumulation of cellular debris and 
extracellular lipids, forming a so-called necrotic core (Figure 1.1:3 D) [31]. These plaques 
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lead to clinical manifestations by producing flow-limitations and hence to tissue ischemia or 
by forming thrombi that can roam into distal arteries [1].  
 
 
Figure 1.1:3 Development of atherosclerotic lesions (adapted from [1]). (A) Normal artery consisting of 3 
layers. The intima is covered with a monolayer of endothelial cells and in contrast to a lot of animal models, 
the human intima contains resident SMCs. The media is a SMC layer embedded in extracellular matrix. The 
adventia constitute the outer layer of arteries and contains mast cells, nerve ends and microvessels. (B) Initial 
steps of atherosclerosis including binding of leukocytes, migration of these into the intima, maturation of 
monocytes into macrophages and the resulting foam cells. (C) Later stage of lesion development showing the 
migration of SMC into the intima and their proliferation. SMC produce extracellular matrix molecules like 
collagen and elastin. Accumulated dead cells and extracellular lipid form a so-called lipid or necrotic core. 
(D) Formation of a thrombus as a result of disruption of atherosclerotic plaque. The fracture of the fibrous 
cap enables blood coagulation that extends into vessel lumen and disturbs blood flow. 
Throughout this process of migration and proliferation, vascular SMCs (VSMCs) exhibit a 
diverse range of phenotypes. Literature often refers to contractile and synthetic phenotypes 
[32, 33], but this 2-stage model does not describe all variations of VSMCs at the different 
stages of atherosclerosis. Morphological, biochemical, physiological and molecular 
properties are also changing within different lesion types and in between different location 
of the SMCs [34]. SMCs in the intima have shown increased expression of proliferative 
markers and decreased expression of proteins characteristic for differentiated VSMC like 
smooth muscle  actin (SM  actin) or smooth muscle myosin heavy chain (SM MHC) [35-
37]. A switch in actin expression from  actin to the  form is detected within the 
A 
D C 
B 
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transformation of SMC from a contractile into a synthetic type. The actin protein is usually 
expressed in fibroblastes and therefore the dedifferentiated cells are also called 
‘myofibroblasts’, combining features of SMCs and fibroblasts [32].  
For proliferation of VSMC, an increase of cytosolic intracellular calcium (Ca2+) is needed 
[38]. Enhanced Ca2+ is needed for cell cycle progression at G1/S phase and cell division in M 
phase [39]. The intracellular Ca2+ is actuated by the balance between Ca2+ influx from 
extracellular through voltage-dependent calcium channels, Ca2+ release from stores in the 
sarcoplasmic reticulum and Ca2+-lowering regulators such as Ca2+-transport ATPases [40]. 
Furthermore, Ca2+ is important for the regulation of the tonus of vasculature - the 
contraction of VSMC is triggered by Ca2+ current through the voltage-gated calcium 
channels [40, 41]. During the development of atherosclerosis, alterations in calcium 
handling in VSMC are found [42, 43]. The dedifferentiation of VSMC during atherogenesis 
is associated with reduced expression [44] and function [45] of L-type calcium channels 
(LTCCs). So LTCCs seem to play a role in the development of atherosclerosis and may 
trigger loss of contractility and proliferation in VSMCs. The exact mechanism behind this is 
still not fully clarified and further examination is needed. 
1.2. Voltage-dependent calcium channels 
As described above in the context of VSMCs, the Ca2+ ion is important for various biological 
processes. Ca2+ entry into the cell in response to membrane depolarization through voltage-
dependent calcium channels (VDCC) initiates muscle contraction, endocrine secretion, 
neurotransmission and gene transcription [41, 46-48]. There are different types of VDCCs 
which are distinguished by their diverse physiological and pharmacological properties. 
This distinction led to an alphabetical nomenclature for the different classes of calcium 
currents (see Table 1.2:1) [49].  
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Table 1.2:1 Extract of the classification of voltage-gated Ca2+ channels by their physiological function and 
pharmacology (adapted from [49]). Not shown is the CaV2 subfamily with P/Q, N and R currents. 
Channel  Current Localization  Specific Antagonists Cellular Functions 
CaV1.1 L Skeletal muscle 
transverse tubules  
Dihydropyridines, 
phenylalkylamines, 
benzothiazepines 
Excitation-contraction coupling 
CaV1.2 L Cardiac myocytes, 
endocrine cells, 
neuronal cell bodies 
and proximal dendrites  
Dihydropyridines, 
phenylalkylamines, 
benzothiazepines 
Excitation-contraction coupling, 
hormone release, regulation of 
transcription, synaptic integration 
CaV1.3 L Endocrine cells, 
neuronal cell bodies 
and dendrites  
Dihydropyridines, 
phenylalkylamines, 
benzothiazepines 
Hormone release, regulation of 
transcription, synaptic integration 
CaV1.4 L Retina  Not established Neurotransmitter  release from 
rods and bipolar cells 
CaV3.1 & 
CaV3.2 
T Neuronal cell bodies 
and dendrites, cardiac 
myocytes  
None Pacemaking, repetitive  firing 
CaV3.3 T Neuronal cell bodies 
and dendrites  
None  Pacemaking, repetitive firing 
 
In VSMCs two types of VDCC are found: L-type and T-type calcium channels [40]. 
T-type calcium channels induce a transient current characterized by rapid inactivation and 
slow deactivation. They activate at highly negative membrane potentials and therefore also 
called low-voltage-activated Ca2+ currents [40, 41]. T-type calcium channels are involved in 
action potential and repetitive firing in a variety of cells [49].  
L-type calcium currents are mediated by the CaV1 subfamily. These currents are 
characterized by high voltage threshold for activation, slow voltage-dependent inactivation 
and long-lasting currents (for barium ions as charge carriers). Therefore they are also called 
high-voltage-activated Ca2+ currents. The L-type calcium channels account for the major 
calcium currents recorded in cardiac, smooth and skeletal muscle and endocrine cells and 
trigger contraction and secretion. In neurons, L-type calcium currents regulate gene 
expression and are important for integrating synaptic inputs [41, 49].  The Cav1 subfamily 
includes four different isoforms (CaV1.1 to CaV 1.4, Table 1.2:1) with different biophysical 
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properties, expression patterns and affinity towards calcium channel blockers. Highly 
specific calcium channel antagonists targeting the LTCC comprise three principal classes: 
1,4-dihydropyridines (DHPs) such as nifedipine, benzothiazepines like diltiazem and 
phenylalkylamines typified by verapamil [50]. The Ca2+ channel block with DHPs is 
isoform-specific and is achieved by selective binding to the inactivated state of LTCCs. This 
implicates a greater blockade of channels in cells with a depolarized resting membrane 
potential (like VSMC) and for channel isoforms showing more rapid inactivation [51]. 
Therefore DHPs are reducing vascular resistance rather than having an effect on cardiac 
contractility. In contrast, the Ca2+ channel blocker verapamil is less voltage-dependent and 
relatively selective for myocardial Ca2+ channels [50].  
Genetic defects in the pore-forming subunit of the LTCCs can lead to loss-of-function or 
gain-of-function mutations, so-called channelopathies [52].  Representatives are the Timothy 
syndrome (CaV1.2, characterized by severe arrhythmia and multiorgan disfunction), 
sinoatrial node dysfunction and deafness syndrome (SANDD, CaV1.3) and night blindness 
(CaV1.4). Interestingly, the mutation found in the Timothy syndrome also alters DHP 
sensitivity and lead to a fourfold increase in IC50 for nisoldipine [53]. 
Cardiovascular voltage-gated L-type calcium channels are heteromeric protein complexes 
consisting of a pore-forming CaV1.2 subunit (also referred to as 1c subunit after prior 
nomenclature [54]), an intracellular subunit and a 2 subunit complex. 
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Figure 1.2:1 The cardiovascular L-type calcium channel complex adapted from [55]. Subunit interaction sides 
are indicated.  The numbers mark important areas for specific channel functions. The EF hand, A, C, and IQ motifs 
represent specific peptide sequences involved in calmodulin (CaM) binding. Red letters in IIIS5, IIIS6 and IVS6 
mark key amino acids required for DHP binding.  
1.2.1. The pore-forming CaV1.2 subunit 
The CaV1.2 pore-forming subunit is the largest subunit with a size of around 190-250 kDa 
and comprises the conduction pore, the voltage sensor, gating apparatus and binding sides 
for channel regulation by second messengers and Ca2+ antagonists. Therefore it determines 
most of the channel’s properties [56]. The CaV1.2 subunit is composed of 4 homologous 
transmembrane domains (I-IV), each consist of 6 segments (S1-S6). The carboxyl- (C) and 
the amino- (N) terminus are located intracellular (Figure 1.2:1).  
The LTCCs are able to respond to activity by self-regulatory mechanisms including voltage-
dependent inactivation (VDI), calcium-dependent inactivation (CDI) and calcium-
dependent facilitations (CDF). These mechanisms arise mainly from the interaction of 
CaV1.2 with  subunits or the calcium sensor calmodulin [57]. The calcium-binding protein 
calmodulin (CaM) is binding to the IQ motif at the C-terminus of the pore and mediates the 
CDI and CDF of the channel [58]. The CDF in smooth muscle and cardiac cells thought to be 
caused by a combination of phosphorylation by Ca2+ /calmodulin-regulated protein kinase 
II (CaMKII) and the described binding of Ca2+/CaM [41]. The CaMKII also interacts with the 
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C-terminus in a region close to the IQ motif leading to phosphorylation of two C-terminal 
sites in the channel and subsequent increase of Ca2+ influx [59].  
The gene of the pore-forming subunit CaV1.2 is subject to extensive alternative splicing.  The 
resulting splice variants lead to distinct physiological [53, 60, 61] and pharmacological [62-
65] properties of the LTCC. Cell-specific expression of alternatively spliced exons increases 
the functional variations for specific cellular activities in response to changing physiological 
signals [66]. 
 
 
Figure 1.2:2 Schematic transmembrane topology of the pore forming CaV1.2  and protein segments encoded 
by numbered exons (adapted from [66]). Spliced exons are marked in different color codes. 
An example for different tissue distribution of alternatively spliced exons is the proposed 
genotypic structure of a “smooth muscle” and “cardiac muscle” isoform of CaV1.2. The 
splice variant for cardiac muscle is supposed to consist of the splice combination 1a/8a/ 
exclusion of 9*/31 while the proposed smooth muscle splice combination is 1/8/9*/32. These 
differential splice pattern (in particular exon 9*) of CaV1.2 also contributes to the more 
hyperpolarized activation properties of the smooth muscle LTCC compared to the 
analogous Ca2+ channels found in heart [60, 66]. Furthermore, a recent study discovered the 
role of exon 9 as a binding side for Galectin-1, a protein reported to regulate VSMC 
function. Galectin-1 only binds to the I-II loop in the absence of exon 9* and lead to a 
decreased surface expression of LTCCs [67].  
The mutually exclusive exons 8/8a encoding for the IS6 segment have been shown to 
modulate sensitivity to DHPs - the inclusion of 8 instead of 8a conferred a higher sensitivity 
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to DHPs and therefore contribute to the tissue selectivity of DHPs [64, 65]. In contrast, the 
exons encoding for the other DHP binding sites, i.e. IIIS5, IIIS6, and IVS6, are constitutive 
exons not subject to alternative splicing. The sensitivity to DHPs can also change with 
differently spliced exons of CaV1.2 not involved in DHP binding. For example, the splice 
shift of mutually exclusive exons 21/22 leads to a reduced sensitivity to DHPs with exon 21 
[62, 63]. 
Recently, several studies examine the association of altered splicing of Cav1.2 with various 
diseases. One example is the alternative splicing of exon 31 and 32. In fetal heart, exon 32 is 
predominant whereas the main isoform of Cav1.2 in adult heart contains exon 31. In human 
heart failure, level of expression switch and the fetal isoform containing exon 32 reemerges 
[68].  
Thus alternative splicing of the pore forming CaV1.2 subunit can provide a level of fine-
tuning of channel activity to adapt to specific cellular conditions or in response to various 
signals. As splicing can modulate biophysiological properties as well as pharmacological 
properties of the LTCC channel, it is of importance to find out more about the role of 
different splice variants of CaV1.2 in development and progression of disease.  
1.2.2. The  subunit 
The auxiliary  subunit interacts with a highly conserved motif in the I –II loop of the CaV1.2 
subunit, the so-called  interaction side (AID), and is a major determent of LTCC function 
and expression.  
The primary sequence encoded 5 domains with V1, V2 and V3 as variable domains and C1 
and C2 as conserved domains (Figure 1.2:3). Structural studies discovered a SH3 domain 
(Src homology 3 domain) and a nucleotide kinase (NK) domain formed by the C1 and C2 
domains, respectively [57]. The two regions are connected by a HOOK domain (V2), the N- 
and C-termini are formed by the V1 and V3 region. A high-resolution crystal structure of 
the -AID complex revealed an  binding pocket (ABP) in the deep groove at the distal end 
of the  NK domain that interacts with the AID motif of the pore forming CaV1.2 [69]. 
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Figure 1.2:3  (A)The -AID complex structure adapted from [57].  Shown is the 2a- CaV1.2 AID complex with 
the SH3 region indicated in green and the NK domain indicated in blue. V1, V2 and V3 show the locations of 
the 3 variable domains that are absent from the structure. The AID, marked in red, binds to a deep groove in 
the NK domain – the  binding pocket (ABP). (B) Model of how the subunit effects the CaV1.2 gating 
(adapted from [57]). The  subunit influences the movement of IS6.  (C) Block diagram of the five domains of 
the  subunit according to sequence homology among all  subunit isoforms. The SH3 and guanylate kinase 
(GK) domains are highly conserved whereas regions V1, V2 and V3 are variable. 
Four  subunit isoforms are known, 1 to 4, and each is subject to alternative splicing 
which leads to further isoforms [41]. The alternative splicing is particularly found in the 
variable V1 (N-terminus) and V3 (C-terminus) domains and in the so-called HOOK domain 
(V2). In most cell types, all four gene products are expressed at a small scale, but the 
proteins show a differentiated subcellular distribution. In skeletal muscle mainly 1a is 
found [70, 71], 2 is the most abundant isoform in cardiac muscle [72, 73] and 4 is the 
predominant isoform in the cerebellum [74]; 3 is mostly expressed in brain [71, 75]. 
The exon structure of the 2 subunit is quite complex. The β2 subunit is encoded by 20 
exons, which are alternatively spliced. Depending on the splice variant, it comprises 13 to 14 
exons and has a highly variable N-terminus [71, 76].  
 
 
 
 
 
 
C 
B A 
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Figure 1.2:4 Splice variants of the human 2 subunit adapted from [71]. Exons are numbered; the exons 
indicated by additional letters are alternatively spliced variants. The names of splice variants are, from left to 
right columns, those used in this study, those proposed by Foell et al. 2004 [76] , and those proposed by Yang  
and Berggren 2006 [77]. 2a is the only splice variant that can be palmitoylated (indicated by the wave). 
The subunits can modulate biophysical properties and cell surface expression of the 
channel. Building a complex with the pore-forming subunit, they lead to increased L-type 
calcium currents [78, 79], which is also demonstrated by single-channel measurements [79, 
80]. Interestingly, all isoforms have different effects on kinetics and voltage-dependence of 
gating. Therefore, complexes with different  isoforms can lead to altered LTCC function 
[41, 57, 79, 81].  
The variable length of the N-terminus of the 2 splice variants described above has 
particular effects on open probability, availability and peak current of LTCC. The extent of 
modulation correlates with the length of the N-terminus and follows a consistent rank order 
in single-channel measurements of human channel complexes (2a≈2b>2e≈2c>2d) [80]. 
A length-dependent modulation of gating could also be shown for the 1 subunit. Here 
inactivation rate was diminished by N-terminus truncation of the wildtype 1a subunit in 
deletion mutants [82]. 
Furthermore, all four  subunit isoforms increase surface expression of the LTCC complex. 
One hypothesis postulates that the I-II loop of the CaV1.2 subunit contains an endoplasmic 
reticulum (ER) retention signal that inhibits the plasma membrane expression of the pore 
subunit. The  subunit reverses this inhibition by aborting an expression brake contained in 
-binding CaV1.2 sequences [83]. Recently, a study purpose a C-terminus dependent 
rearrangement of intracellular domains of CaV1.2 with binding of the  subunit to the I-II 
loop and subsequent a shift in balance of power between export signals in the I-II loop and 
retention signals elsewhere in the CaV1.2 subunit [84]. Another recent study suggests that 
the increased CaV1.2 membrane expression is due to the prevention of its ubiquitination and 
 Introduction 
- 13 - 
proteasomal degradation by the  subunit [85]. Thus the  subunit may be necessary to 
protect CaV1.2 against degradation.  
1.2.3. The 2 subunit 
The 2 subunit complex is encoded by a single gene and is posttranslationally cleaved. It 
consists of a large extracellular (2) and a transmembranic component () and the complex 
is linked via a disulfide bond (Figure 1.2:5) [86].  
 
 
Figure 1.2:5 Structure of the α2δ subunit within the Ca2+ channel complex, illustrated as a cartoon adapted 
from [87]. The 2 protein is located outside of the cell is linked via disulfide bridges to the  protein. The 
approximate position of the VWA domain in the α2δ subunit is indicated. There are many potential 
glycosylation sites in α2δ; the representation of these sites shown here does not accurately reflect the number 
of sites. 
The 2 subunit is necessary for proper cell surface expression of the LTCC complex. It 
promotes trafficking of the CaV subunit to the plasma membrane and increases retention in 
the membrane [71]. The 2 subunits can also modify biophysical properties: in 
heterologous expression system it affects LTCC function by increasing channel density and 
charge movement [55]. It remains unclear how strong it also affects channel function under 
physiological conditions.    
The 2 subunit is main target for certain GABA-antagonists such as gabapentin [88], an 
anti-epileptic and analgesic drug, and the anti-neuropathic pain drug pregabalin [89].  
Upregulation of 2is associated with neuropathic pain [90]. 
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1.3. Aim of the study 
Arterial smooth muscle cells undergo multiple phenotypic changes during the development 
of atherosclerosis. Atherosclerosis is also associated with a reduced expression and function 
of the L-type calcium channels in VSMCs. In a study from 2006, Tiwari and colleagues 
discovered an important structural change of the CaV1.2 subunit in human atherosclerotic 
lesions, i.e. an exon switch of the alternative exon 21/22 encoding the second 
transmembrane helix of domain III (Figure 1.3:1 A). In particular, a variety of arterial 
smooth muscle CaV1.2 isoforms all containing exon 21 (CaV1.2ex 21) were reported to be 
replaced by one single isoform containing the alternative exon 22 (CaV1.2ex 22). This 
postulated splice shift of exon 21/22 is of particular importance since the two splice variants 
lead to a different sensitivity to DHPs [62, 63]. They characterized and compared the 
resulting heteromultimeric channel complexes expressed in Xenopus oocytes without 
detecting major functional consequences in the exon switch [91]. However, they focused on 
channels coexpressed with 1a subunits, whereas the main  subunits present in smooth 
muscle cells are considered to be 3 (and maybe 2) subunits [92]. As described above, the 
different  subunit isoforms are major determents for channel function and expression.  
Therefore, our group examined the two human splice variants of CaV1.2 containing either 
exon 21 or exon 22 (here named 1c 70 and 1c 77, respectively) in the context of different  
subunit isoforms. The data of Tiwari et al. could be confirmed in the context of a 1a 
subunit in HEK 293 cells. However, strikingly different results were obtained coexpressing 
these pore subunits with either 2b or 3a subunits (Figure 1.3:1 B). 
 The splice variant of CaV1.2ex22 found in atherosclerotic VSMC gave rise to a markedly 
reduced whole-cell current when coexpressed with 3a subunits. In contrast, coexpressed 
with a 2b subunit the splice shift had the opposite effect, i.e. higher current density with 
the exon 22 containing Cav1.2 isoform. Both effects could be partially -but not 
quantitatively- be explained by the single-channel properties (Figure 1.3:1 C).  
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Figure 1.3:1 Modulation of L-type Ca2+-current by β subunits in HEK cells expressing CaV1.2ex21 (1C,70) or 
CaV1.2ex22 (1C,77) splice variant. (A) Alternative splicing of exon 21/22 leads to a different III/S2 helix of CaV1.2 
in human atherosclerotic smooth muscle cells [91]. (B) Amino acid sequence of exon 21 and exon 22.  
(C)Whole-cell currents through 1C,70 and 1C,77 were  similar when coexpressed with 1a (-5.6 ± 1.2 pA/pF vs. -
6.2 ± 1.2 pA/pF). In contrast, 2b and 3a subunits distinctly modulated currents of 1C isoforms. Currents 
through 1C,77 were significantly lower when coexpressed with 3a (1C,77 3a:: -1.1 ± 0.3 pA/pF vs. 1C,70 3a: -4.2 ± 
0.5 pA/pF). Conversely, 2b-coexpression led to higher activity with 1C,77 (1C,77 2b: -4.2 ± 1.3 pA/pF vs. 1C,70 2b: 
-1.7 ± 0.6pA/pF). Compared to the respective 1a series, currents were significantly lower with 1C,702b and 
1C,77 3a. Holding potential: -80mV; pulse duration: 100ms; test potential: -40 to 60 mV. Also shown is the 
ensemble average single-channel current of CaV1.2ex22 and CaV1.2ex21 plus indicated β subunit (Rottlaender et 
al., unpublished). 
The reduced currents in context with the 3 subunit led to the hypothesis that the observed 
splice shift of Cav1.2 may be the structural mechanism of the calcium current 
downregulation in diseased arterial smooth muscle cells. Single-channel data could not 
fully explain the different effects of the two  subunits (Figure 1.3:1 C).  
These results illustrated the need to examine the expression pattern of all calcium channel 
subunits in atherosclerotic human tissue and in relevant mouse models. The aim of this 
study is to understand the role of differential calcium channel subunit expression in the 
development of atherosclerotic vessel changes, i.e. smooth muscle cell proliferation and 
neointima formation. Does the observed splice shift of CaV1.2 in context with a 3 subunit 
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induce Ca2+ current remodeling associated with the dedifferentiation of SMC? And is this 
splice shift correlated with a differential expression of auxiliary subunits of CaV1.2? 
To address these questions, vascular smooth muscle cells from human diseased arteries 
were isolated by laser capture microdissection. Subsequently, mRNA of calcium channel 
subunits was quantitatively determined by real-time PCR in unaffected and atherosclerotic 
samples. The focus was on the  subunit isoforms as they have been shown to effect LTCC 
function in the context of the two splice variants of CaV1.2. 
To complement this approach, Apo E knockout mice (apoE -/-) served as model organism 
for atherosclerosis [93]. Aorta from these mice and the correspondent wildtype were 
examined to test the hypothesis that a similar splice shift of CaV1.2 can be detected in 
murine atherosclerotic lesion. Furthermore,  subunits were quantitatively examined via 
real-time PCR (qRT-PCR) to test the hypothesis of differential expression of  subunits in 
the development of atherosclerosis. 
Prevailing murine channel complexes were expressed in HEK293 cells followed by 
electrophysiological assessment to facilitate insight into function of murine LTCC in VSMC 
in health and disease. 
LTCC channel subtypes are targets for drugs for cardiovascular disease and play a role in 
dedifferentiation of VSMCs in atherosclerosis. The understanding of the molecular 
composition of the L-type calcium channel complex in health and disease and subsequent 
functional analysis will provide insights into the development of atherosclerosis and may 
lead to new ways to modulate LTCC function in pathological states.   
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2. Materials and methods 
2.1. Messenger RNA (mRNA) analysis of human arterial 
samples 
2.1.1. Human sample collection 
Samples of human atherosclerotic arteries were obtained from patients undergoing 
carotid or femoral bypass surgery in the department of vascular surgery of the 
University Hospital of Cologne. This study was approved by the ethics committee of the 
University of Cologne (07-203; 11/2007), and participating patients gave written informed 
consent. Biopsies were taken from femoral or carotid arteries and their side branches 
during surgery, immersed in 2-methylbutan (Roth, Karlsruhe, Germany) and directly 
flash frozen in liquid nitrogen. The rare control samples were taken from patients who 
had a stent surgery or amputations due to non-atherosclerotic reasons (e.g. traumatic 
rupture of arteries). 
 
Table 2.1:1 Patient characteristics of arterial samples evaluated in this study. The methods used for 
investigation included mRNA analysis of whole tissue sample (WTS) and analysis after isolation of 
vascular smooth muscle cell areas via laser  capture microdissection (LCM).  
patient  sex  age arterial tissue  method cardiovascular risk factors 
3 f 78 carotid LCM none 
5 m 62 carotid LCM none 
6 m 66 carotid LCM hypertension 
8 f 82 femoral LCM not known 
9 m 65 femoral LCM none 
10 m 59 carotid WTS hypertension 
12 m 62 carotid LCM cerebralvascular 
insufficiency (CVI) 
17 m 75 femoral WTS hypertension, diabetes 
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patient  sex  age arterial tissue  method cardiovascular risk factors 
18 m 64 carotid LCM hypertension, 
hypercholesterolemia 
19 m 75 Aorta abdominalis WTS hypertension, 
hypercholesterolemia 
20 
 
m 70 branch carotid WTS hypertension, diabetes, 
heart failure, smoking 
21 m 67 femoral WTS not known 
26 m 72 Aorta abdominalis WTS hypertension 
30 m 78 branch femoral WTS hypertension, 
hypercholesterolemia, 
smoking, atrial fibrillation 
34 m 83 branch femoral 
control sample 
 
WTS non-atherosclerotic, 
smoking, benign 
hypertension 
36 f 75 femoral           
control sample 
WTS non-atherosclerotic, 
hypertension, smoking 
37 m 85 femoral LCM diabetes, hypertension, 
heart failure, angina 
pectoris 
39 f 68 femoral LCM hypertension, alcoholism 
40 m 63 branch femoral WTS hypercholesterolemia, 
hypertension 
41 f 68 femoral LCM hypertension 
43 m 62 femoral WTS hypercholesterolemia 
46 m 84 branch femoral WTS coronary heart disease, 
atrial fibrillation, diabetes, 
hypertension 
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2.1.2. Laser capture microdissection (LCM) and Immuno-
histochemistry 
The arterial biopsies were imbedded in Tissue Tek O.C.T compound (Sakura Finetek 
Europe, Leiden, Netherlands) and cut in serial cryostat sections (5-7 m thick) with a 
cryostat (Leica Microsystems, Nussloch). Every first and third cut was placed on a 
Superfrost plus slide (Menzel, Braunschweig) for immunohistochemistry; every second 
and fourth cut on polyethylen membrane slides (Zeiss, Munich) for LCM.  Every slide 
contained 5 to 6 serial cuts.  
Serial cuts for the immunohistochemistry were dried overnight and then fixed in an 
acetone/ methanol mixture (1:1).  For immunostaining, two antibodies were used: anti-
human smooth muscle actin (SMA; DAKO, Glostrup, Denmark) which marks smooth 
muscle cells (SMC) and myofibroblasts and anti-Ki67 (DCS, Hamburg, Germany) which 
marks a nuclear protein that is expressed in proliferative cells. Immunostaining was 
done automatically by an Autostainer (Medac, Wedel, Germany) following a standard 
protocol. 
After assessment of different fixation methods for subsequent LCM, the following 
method was picked to be the most effective one for further RNA isolation: 
For LCM, serial cryostat sections were fixed in ice-cold ethanol and after short drying 
period stored at -80°C. To increase the visibility of cell structures, nuclei were stained 
with hemalum, a complex formed from aluminum ions and oxidized haematoxylin (HE 
staining; Merck, Darmstadt, Germany) right before LCM. Slides were dried at 50 °C for 
10 minutes. 
Cuts were characterized with the help of the immunostainings and histology and 
grouped as atherosclerotic areas and non-affected areas (see chapter 3.1.1). 
Laser capture microdissection (PALM Microlaser Technologie, Benried; Zeiss, Munich, 
Germany) was then used to isolate selected SMC areas. With the corresponding software 
palmwin® all relevant parameters were regulated, like laser focus and energy. Energy 
was regulated due to consistence and humidity of the cuts.  Circles with a diameter of 
around 100 m were cut with the help of a precisely controlled laser. 20 to 30 of these 
selected areas were then catapulted vertically via laser pulse into an adhesive cap (Zeiss, 
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Munich; Figure 2.1:1.). After collecting the SMC areas, the cap was deep frozen in liquid 
nitrogen and stored at -80 °C.  
 
 
Figure 2.1:1: Principle of the non-contact  laser  capture microdissection  (www.Zeiss.dk). 
Variation within this method to find optimal conditions included different fixation and 
HE staining protocols, increased cell amounts and fractional snap freezing with 
subsequent pooling of microdissected areas of different serial cuts. 
2.1.3. Isolation of RNA from microdissected samples 
The total RNA of the microdissected SMC areas was isolated following the protocol of 
the NucleoSpin RNA XS kit (Machery-Nagel, Düren, Germany). The microdissected 
VSMC samples in the cap were centrifuged to transfer the samples into tris-(2-
carboxylethyl)-phosphine hydrochlorid (TCEP) containing RA1 buffer. The samples 
were then homogenized by vortexing for 30 seconds and 20ng of carrier RNA was added 
to the lysate. DNA was removed with on-column DNAse digestion included in the kit. 
The RNA was eluted in a volume of 20 l. 
At the end of the isolation protocol, concentration of RNA was determined by measuring 
the absorbance at 260nm using a Nanodrop 2000 (Thermo Scientific, Wilmington, USA). 
As a mark of quality, the ratio 260/280 nm had to be between 1.8 and 2.0. As RNA 
concentrations were very low, quality was exemplary tested with a RNA pico LabChip® 
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(Agilent RNA 6000 Pico Kit) on an Agilent 2100 bioanalyzer (both from Agilent, 
Waldbronn, Germany) according to the standard manufacturer’s protocol.  For 
measurements, 1 l of RNA samples were loaded onto the chip. The RNA integrity 
number (RIN) is a software tool to compare integrity of RNA samples [94] and was taken 
as a quality marker. The isolated RNA was stored at -80 °C. 
As an alternative approach, the RNeasy Micro kit (Qiagen, Hilden, Germany) was used 
to find optimal isolation efficiency. Controlled by RNA pico LabChip® (s. above) there 
was no significant difference in RNA isolation efficacy and quality of RNA. 
2.1.4. Isolation of RNA from whole-tissue samples 
Isolation of RNA from whole arterial biopsy samples was carried out with the RNeasy 
lipid tissue mini kit (Qiagen, Hilden, Germany) following the protocol. Deep-frozen 
arterial biopsies were homogenized with an Ultra Turrax ® (IKA, Staufen, Germany) in 1 
ml of QIAzol lyisis reagent.   
The total RNA concentration and 260nm/280nm ratio was measured with a Nano Drop 
2000 (Thermo Scientific, Wilmington, USA). As a quality control, the 260nm/280nm had 
to be between 1.8 and 2.0. A selection of RNA samples were tested with a RNA pico 
LabChip® as described above.  The isolated RNA was stored at -80°C. 
2.1.5. Reverse transcription into complementary DNA  
The isolated RNA was used as a template to synthesize complementary DNA (cDNA) 
with the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) following 
manufacture’s protocol. In brief, 12 l of the RNA from microdissected samples were 
reverse transcribed to get highest cDNA amounts whereas 400 g RNA was used from 
the whole tissues samples in a final volume of 20 l. Reverse transcriptase master mix 
contained a mixture of oligo-dT (deoxy-thymine) and random primers for high cDNA 
yields from all regions of RNA transcript.  The following temperature protocol was used: 
5 minutes at 42 °C for DNA digestion, 20 minutes at 42 °C for reverse transcription and 3 
minutes at 95 °C to inactivate the reverse transcriptase.  The resulting cDNA was stored 
at -20°C.  
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2.1.6. Quantitative real-time PCR  
Quantitative real-time PCR (qRT-PCR) was chosen to quantify the gene expression of the 
subunit isoforms of the L-type calcium channel (LTCC). This method is highly sensitive 
to low amounts of target and facilitates detection in the early exponential phase of PCR 
in real time which is seen in figure 2.1.6:1 [95]. Therefore a so-called threshold is set to a 
value above the background fluorescence and within the log linear phase of the PCR. 
The detection during the PCR is achieved by using the fluorescent dye SYBR green 
which binds all double stranded DNA molecules (s. figure 2.1.6:1 A).To avoid false 
positive detection of genomic DNA, primers were designed intron-spanning or intron-
flanking in the case of long flanked introns. Melting curve analysis at the end of each 
measurement assured exclusion of detecting primer dimers or unspecific amplicons 
(figure 2.1.6:1 C).  
Low concentrations of specific LTCC subunit-containing plasmids were used to confirm 
that primer pairs are only detecting the specific isoform of subunits. Conventional PCR 
and agarose gel electrophoresis had to lead to a band of amplified cDNA only with their 
respective primer pair. In the case of the exon 21- and exon 22-distinguishing primer 
pairs, qRT-PCR products of whole-tissue samples were sequenced using Eurofins mwg/ 
operon sequencing services (Ebersberg, Germany). 
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Figure 2.1:2: Principle of SYBR green detection of double stranded DNA (A; [96]). (B) Example of a qRT-
measurement indicating the threshold and the setting of threshold cycle (Ct)-value. (C) Melting curve 
analysis at the end of each qRT-PCR. 
For qRT-PCR analysis of the human samples, a master mix was prepared containing 2.5 
l cDNA, 10 l Quanti Tect SYBR Green PCR master mix (Qiagen, Hilden, Germany) 
and 5.5 l H2O per target/ primer pair used for detection (table 2.1.6:1). This master mix 
was placed into a LightCycler® glass capillary and 1 l forward and 1 l reverse primer 
(10 mM) was added. Besides the primer pairs for the genes of interest 18S RNA was used 
as reference genes for the amount of analyzed cDNA. 
 
Table 2.1:2 Specific primer used to detect different isoforms of the LTCC subunits. Primers were 
designed intron-spanning or intron-flanking to avoid detecting genomic DNA. F stands for forward 
primer and R for reverse primer. 
Primer name Sequence Gene ID 
β1 common 
 
F 5’ – AAT GTT GGC TAC AAT CCG TCT C –3’  
R 5’– CCG ATC CAC CAG TCA TTA TTG T–3’  
CACNB1 
 
β2  common 
 
F 5’ – CAA CGT CCA GAT GGT AGC AG-3’  
R 5’ – CTC CAG ATA GTC GGC AAG GT –3’  
CACNB2 
β3 common 
 
F 5’- GTC CTC CCA GTG CCA TCC-3’  
R 5’– ATC AGA GGG CAT CAA GCT GT –3’  
 
CACNB3 
 
A B 
Threshold 
CT-value 
C 
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Primer name Sequence Gene ID 
β4 common 
 
F 5’- CAC CAT ATC CCA CAG CAA TTT-3’  
R 5’- AGT TCT CTG TGG AGT GGT TGC T –3’  
CACNB4 
α1c common 
 
F 5’- CAC GAT CTT CAC CAA CCT GA-3’ 
R 5’- CTG AAG GAG GTG TGC TGG A-3’ 
CACNA1C 
Exon 22 
 
F 5’ -ATC CTA GGC AAT GCA GAC TAT GTC – 3’ 
R 5’-AAA GCC CCA TAA GCA GTC ATC T-3’ 
 
Exon 21  F 5’ – CAC CAT TGA AAT TGC TCT GAA G –3’ 
R 5’- CAG GTC CAG GAT GTT GAA GTA GT –3’ 
 
 
18S RNA F 5’ - AAA CGG CTA CCA CAT CCA AG –3’ 
R 5’-  CCT CCA ATG GAT CCT CGT TA –3’ 
Rn18S 
 
Before analysis, glass capillaries were spin down using a LightCycler® centrifuge. qRT-
PCR analysis was performed with a carousel-based LightCycler  (Roche Applied Science, 
Mannheim, Germany) and LightCycler® software 3.5.3 The following temperature 
protocol was used: 
 
95°C    15 min 
95°C    15 sec 
60°C    25 sec                 45 cycles, transition rate 20 °C/ sec 
72°C    10 sec 
Melting curve analysis 
64°C    1 min 
Heat up to 94 °C, transition rate 0.1 °C/ sec and continuous acquisition 
  
The threshold cycle (Ct) is the cycle at which the amplification plot crosses the threshold 
and therefore a significant increase in fluorescence is detected. This value is taken as the 
characteristic value for each target gene in a sample and a lower Ct value correlates with 
a higher template amount. Calculation of the difference between the Ct value of the gene 
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of interest and the Ct value of the reference gene in each sample is used to normalize for 
the amount of template used: 
Ct = Ct (target gene) – Ct (reference gene) 
Relative quantification in qRT-PCR is used to compare differential expression of a gene 
in different tissues or to compare differential expression in different disease states.  
 Ct = Ct 1 - Ct 2 
For statistical analysis student t test of the  ct values was used. 
However, the important point of this method is that the expression level of the reference 
gene must not vary between different tissues or different disease states. Furthermore, the 
amplification efficiency of the different primer assay must be comparable or must be 
included in the calculations.  
Therefore amplification efficiencies were determined by preparing a dilution series for 
each gene from whole-tissue samples. Slope of the standard curve (S) was taken to 
calculate Efficiency (E): 
E = 10 (-1/S) – 1 
If the efficiency of two assays is comparable the standard curves of both genes go in 
parallel. The differences in Ct values of the target and the reference gene will be constant 
even when amounts of template are varied. In this study the efficiency of primer assays 
were comparable and hence the Ct method could be used without further 
normalization. 
For absolute quantification of exon 21 and exon 22, standard curves were prepared using 
oligonucleotides (sigma-alderich, St.Louis, MO, USA) each representing one exon plus 
parts of adjacent exons. The standard curve plots Ct values on the y-axes and log amount 
of standard on the x-axes. Amount of standard was calculated using the following 
formular: 
(X g/l cDNA / (transcript length in nucleotides x 340)) x 6.022 x10 23 = Y molecules/l 
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2.2. Messenger RNA analysis of murine aortic samples 
2.2.1. Mouse model 
Apo E knockout mice (apoE -/-) served as model organism for atherosclerosis [93]. 
Knockout mice were backcrossed into a C57/Bl6 background and heterozygous 
littermates were taken for breeding. Homozygous littermates, not carrying the apoE 
knockout, were used as wildtype controls (wt). Mice had originally a LysMCre 
background which has not been used in this work [97]  
Mice were grouped into three age-classes to cover different stages of atherosclerosis. Age 
groups were chosen due to literature: at the age of 12-14 weeks apoE -/- mice develop 
stage II lesions whereas the older ones evolve stage III and IV lesions [98]. ApoE -/- mice 
were fed with a western-type diet from the age of 4 to 5 weeks to develop atherosclerotic 
plaques earlier than with a common diet. Western-type diet consisted of 21 % fat, 0.15 % 
cholesterol and 19.5 % casein (Altromin, Lage, Germany). To estimate the effect of the 
diets, also small control groups with apoE -/- mice were fed with normal diet and wt 
mice fed with western-type diet (Table 2.2:1). 
All animal procedures were conducted with respective laws and regulations and 
conform to the ‘Guide for the Care and Use of Laboratory Animals’ published by the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996). 
 
Table 2.2:1 Age groups of apoE -/- and wildtype mice fed with either western-type or normal diet used in 
this study.  
Genotype Age diet # in group 
apoE -/- mice 12-14 weeks western-type diet  14 
apoE -/- mice 16-18 weeks western-type diet  8 
apoE -/- mice 22 weeks western-type diet 6 
apoE -/- mice 12-14 weeks normal diet 4 
wildtype mice 12-14 weeks normal diet 10 
wildtype mice 16-18 weeks normal diet 7 
wildtype mice 12-14 weeks western-type diet 6 
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2.2.2. Genotyping 
Genomic DNA (gDNA) was isolated from tail clips of 3-4 week old mice using 
NucleoSpin96 Tissue Kit and NucleoVac96 Vacuum Manifold (Macherey-Nagel, 
Düren, Germany) following manufacturer’s protocol. The following specific primers 
(Metabion, Martinsried, Germany) were used to detect the wt and knockout mice via 
PCR [97]. Wildtype mice show a band at 155 base pairs (bp) whereas the apoE -/- mice 
lead to a 245 bp band on a 1% agarose gel.  
 
Table 2.2:2 Primer pairs used to genotype wt and apoE -/- mice in this work 
primer name sequence 
ApoIMR0180 5’-GCC TAG CCG AGG GAG AGC CG-3’ 
ApoIMR0181 5’-TGT GAC TTG GGA GCT CTG CAG C-3’ 
ApoIMR0182 5’-GCC GCC CCG ACT GCA TCT-3’ 
 
2.2.3. Dissection of the aorta 
Mice were sacrificed by cervical dislocation and the cardiovascular system was 
rinsed with phosphate buffered saline (PBS) by perfusion of the right ventricle. 
The aorta was dissected starting with the descending aorta and including the 
heart (see figure 2.2.2.:1 A). Aorta was separated from the heart right above the 
aortic root and dissected from connective tissue (see figure 2.2.2.:1 B). Only the 
aortic arch was used for further experiments and was flash frozen directly in 
liquid nitrogen. The hearts were cut in the middle and frozen on top of a metal 
cap floating in 2-methylbutan in dry ice to achieve an even cutting surface. Heart 
and aortic arch were stored at -80°C. 
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Figure 2.2:1 (A) Dissected heart of a C57/BL6 wild type mice also showing the aortic arch and descending 
aorta. (B) The aorta and their branches (Henry Gray's Anatomy of the Human Body, 1918). Marked area 
was taken for later experiments. 
 
2.2.4. Characterization of plaque area 
ApoE -/- mice develop increasing stages of atherosclerosis with age. To characterize and 
quantify the atherosclerotic lesions, frozen mouse hearts were sectioned in a cryostat 
(Leica microsystems, Wetzlar, Germany) at -20°C. Therefore hearts were embedded in 
Tissue Freezing Medium® (Leica Microsystems, Nussloch, Germany) and cut in 7 m 
thick serial slices. Slices were collected at the level of atrioventricular valves on 24 
Superfrost plus slides (Menzel, Braunschweig, Germany) following Figure 2.1:1. Slides 
were dried overnight in an exicator at room temperature and then stored at -80°C. 
  
 
Figure 2.2:2: Scheme of collecting the heart cuts starting with the first slide down left and ending with the 
last cut after rounds needed at slide no 24. Hence the interspaces between serial cuts on one slide were 
originally 168 m. 
Staining with Toluidin-blue was used for morphometric analysis and atherosclerosis 
quantification at the level of the aortic valves. For this staining, slides 6, 12, 18 and 24 
1 2 3   24 
73… 
1-25-49 
74… 
2-26-50 
75… 
3-27-51 
96… 
24-48-72 
A B 
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were fixed in 100 % acetone (Roth, Karlsruhe, Germany) and stained with 0.2 % 
Toluidin-blue solution (Roth, Karlsruhe,Germany) in PBS. For morphometric analysis, 
sections were microphotographed with a 4x magnification ocular (Leica microsystems, 
Wetzlar, Germany). Lesion size was measured on four consecutive sections in 42 mm 
intervals using Leica Application suite V3.8.0 (Leica microsystems, Wetzlar, Germany). 
Serial cuts were chosen in the area of the aortic valves where the aortic wall is already 
clearly distinguishable. Average plaque area was taken from these four serial cuts per 
mouse heart [99].  
2.2.5. RNA Isolation 
The deep-frozen aortic arches were disrupted and homogenized in Qiazol® (Qiagen, 
Hilden, Germany) using an Ultra Turrax ® (IKA, Staufen, Germany). Total RNA was 
isolated with the Qiagen RNeasy lipid tissue mini kit following the manufacturer’s 
protocol. DNA was removed with on column DNase digestion included in the kit. The 
RNA was eluted in a volume of 60 l RNase free water. RNA concentration was 
determined by measuring absorbance at 260nm using a Nanodrop2000 ((Thermo 
Scientific, Wilmington, USA). The ratio between the absorbance values at 260nm and 
280nm was taken as a quality control for RNA purity and should fall between 1.8 and 
2.0.  The quality of exemplary samples was tested with a RNA pico LabChip® as 
described above.  
2.2.6. Reverse transcription into complementary DNA (cDNA)  
RNA was reverse transcripted into cDNA using QuantiTect Reverse Transcription kit 
(Qiagen, Hilden, Germany). Therefore 400ng total RNA was used and transcription 
followed manufacturer’s protocol as described above in a total volume of 20 l.  
2.2.7. Qualitative reverse transcription PCR (RT-PCR) 
To detect the presence of the alternative splice variants of the pore-forming CaV1.2 
containing either exon 21 or 22, RT-PCR was used followed by an analytic digestion with 
Avr II (NEB, Frankfurt, Germany). The region spanning exon 18 to exon 27 was 
amplified with the help of PCR using 200 ng cDNA as a template. PCR was carried out 
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using DreamTaqTM DNA Polymerase (Fermentas, Burlington, Canada). Cycling program 
included: 
 
95°C    3 min 
95°C    30 sec 
59°C    30 sec                 40 cycles 
72°C    55 sec 
72°C    5 min 
  
 
Table 2.2:3 Primer pairs used to amplify region between exon 18 and exon 27 of Cav1.2. 
primer name sequence 
Exon18-27 forward 5’-TTA CAG CCG ATG GAG AAT CC-3’ 
Exon18-27 reverse 5’-GTG GAG ACG GTG AAG AGA GC-‘3 
 
After PCR, samples were purified using a DNA gel extraction kit (Millipore, Billerica, 
USA) following manufacture’s protocol. The purified amplicon was then digested using 
Avr II in supplied buffer 4  at 37°C for 2 h to differentiate between exon 21- and exon 22- 
containing Cav1.2.  
2.2.8. Quantitative real-time PCR (qRT-PCR) of murine aortic 
samples 
As described in section 2.1.6, quantitative real time PCR was chosen to quantify the gene 
expression of the subunit isoforms of the L-type calcium channel (LTCC). The same 
protocol was used as described above except small changes which were chosen after 
optimization of the new assays. All ct values are given as mean plus standard error of 
the mean (SEM). 
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Reaction mixture 
10 l SYBR Green Quanti tect mastermix  
2 l template 
1.5 l primer (10 mM) forward (0.75 M) 
1.5 l primer (10 mM) reverse (0.75 M) 
H2O ad 20 l 
The annealing temperature of 58 °C was chosen due to experiments finding the best 
conditions for the cycling protocol of the new primer assays. 
 
Table 2.2:4 Specific primer pairs used to detect the different isoforms of the LTCC subunits. Primers were 
designed intron-spanning or intron-flanking to avoid detecting genomic DNA. F stands for forward 
primer and R for reverse primer. 
primer name sequence gene 
1 subunit  
 
F 5’- TGG ACA GCC TTC GTC TGC T -3’ 
R 5’- TGG AAC TGG AGT TGT CAC CT -3’ 
CACNB1 
2 subunit F 5’- GGG AGG CAG TAC GTA GAG AAG CT -3’ 
R 5’- TGC AAA TGC AAC AGG TTT TGT C -3’ 
CACNB2 
3 subunit F 5’- TGG AGT CAA CTT TGA GGC CA -3’ 
R 5’- TCC CGA TCC ACC AGT CAT TG  -3’ 
CACNB3 
CaV1.2 subunit F 5’- TCC GAA CAT TAC AAC CAG CCT -3’ 
R 5’- GCT GTA CAT CTT CAG GAG CA -3’ 
CACNA1C 
Exon 21 F 5’- CAC CAT TGA AAT TGC TCT AAA G -3’ 
R 5’- CAG GTC CAG GAT ATT GAA GTA GT -3’ 
Z34810 
Exon 22 F 5’- ATC CTA GGC AAT GCA GAC TAT GTC -3’ 
R 5’- AAA GCC CCG TAA GCA GTC ATC T -3’ 
Z34815 
2a (N3) F 5’- AGT GCT GCG GGC TGG TAC -3’ 
R 5’- AAC CAT AGG ACA CCC GTA CTC -3’ 
FM872406 
2b (N4) F 5’- ATG CTT GAC AGG CAG TTG GT -3’ 
R 5’- CCC CAG GAA TAC TGG ATT -3’ 
AM259383 
2d (N1) F 5’- ATG GAA GCA CAT CGT CAG ACA CT -3’ 
R 5’- CCT GCC GCT CAG CTT CTC TA -3’ 
FM872408 
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primer name sequence gene 
2e (N5) F 5’- GAA GGC TGA AGA GTT CGG ACA T -3’ 
R 5’- CCT GCC GCT CAG CTT CTC TA -3’ 
FM872407 
S29 F 5’- ATG GGT CAC CAG CAG CTC TA -3’ 
R 5’- AGC CTA TGT CCT TCG CGT ACT -3’ 
Rps29 
 
Specificity of primer assays for the different isoforms of LTCC subunits was tested using 
low concentration of plasmid carrying the target sequence. As described in chapter 2.1.6, 
standard curves of pooled aortic tissue were used for determination of efficiency of 
primer assays. All efficiencies were comparable and hence no further normalization was 
necessary. 
2.3. Electrophysiology 
2.3.1. Plasmids  
The LTCC channel complexes investigated in this work are composed of only murine 
subunits. The pore-forming CaV1.2 subunits and  subunits are all kindly provided by 
Veit Flockerzi (Saarland University, Homburg, Germany). pGFP+ was used as an 
indicator for successfully transfected cells and was kindly provided by Alexandra 
Koschak (University of Innsbruck, Austria). All vectors used in this study carry an 
ampicillin resistance gene. 
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Table 2.3:1 Plasmids used in this study to investigate function of murine LTCC in HEK293 cells.  
Name Gene Accession # vector publication 
CaV1c KN CACNA1C FM 872412 pcAGGS M2 [100] 
CaV1c Cl16K CACNA1C s. table 2.3.2:2 pcAGGS M2 [100] 
CaV N1 (2d) CACNB2  FM 872408 pcAGGS M1 [100] 
CaV N4 (2b) CACNB2 AM 259383 pcAGGS M1 [100] 
CaV 3A CACNB3 protein P54285-1 pcDNA3 [101] 
CaV 2-1 CACNA2D1 NM_001110843.1 pcDSA3  
pGFP+    [102]  
 
The pore-forming CaV1.2 splice variants were both characterized by a short N-terminus 
which is characteristic for smooth muscle cell Cav1.2 splice variants [60]. The splicing 
pattern is as follows (only typical alternatively spliced exons are shown): 
 
Table 2.3:2 Splicing pattern of CaV1.2 1c  clones (modified after [100]) 
plasmid 1A/1B 7/7* 8A/8B 9A 17/17* 21/22 31/32 33/33* bp 
CaV1c KN 1B 7 8B 9A 17 21 31 - 6462 
CaV1c Cl16K 1B 7 8B 9A 17 22 31 - 6462 
 
The plasmid encoding the cDNA of 2-1 subunit was originally provided by Norbert 
Klugbauer (University of Freiburg, Germany) in a pBluescript vector. In order to transfer 
the cDNA into a mammalian expression vector, the coding cDNA of 2-1 was cloned 
into a pcDSA3 vector (low copy variant of pcDNA3) as described in chapter 2.3.2.4. 
Sequence was confirmed by sequencing. 
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2.3.2. DNA cloning and subcloning 
2.3.2.1. Preparation of Escherichia coli (E.coli) competent cells  
 
Lysogeny broth (LB) medium (all components from Roth, Karlsruhe, Germany) 
1% (w/v) peptone  
0.5% (w/v) yeast extract 
1% (w/v) sodium chloride 
pH 7.5, autoclaved  
 
Transformation and storage buffer (TSB) 
10% (w/v) PEG 3000 
5% (w/v) DMSO 
20 mM MgCl2 
LB medium 
pH 6.5, filtered sterile 
 
The bacterial strain JM109 is a useful host for cloning. The cell stock-solution (Promega, 
Madison, WI, USA) was plated on a LB ager and incubated over night at 37°C. Each 
picked colony was transferred into 10 ml LB medium and was again incubated 
overnight. 5-10 ml was transferred into a final volume of 250 ml LB broth and let grow to 
an OD600 of 0.3-0.4. The bacteria were harvest by centrifugation at 5000 rpm and 4 °C for 
10 min. The pellet was then gently resuspended in 25 ml ice-cold TSB and incubated on 
ice for 1-2 h. Aliquots were stored at -80°C. 
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2.3.2.2. Transformation of E. coli competent cells 
 
KCM buffer (all components from Roth, Karlsruhe, Germany) 
500 mM KCl 
150 mM CaCl2 
250 mM MgCl2 
H2O 
 
Aliquots of bacteria were thawed on ice. 100 l of this bacteria suspension was mixed 
with 20 l of 5xKCM buffer and 80 l H2O.  10 ng of plasmid DNA was added and 
incubated for 20 min on ice and for 10 min at room temperature. After adding 1 ml of LB 
medium the mixture was incubated shaking at 37°C for 50 min. It was centrifuged for 30 
sec and the pellet was resuspended in 50 ml fresh LB medium and plated on an 
ampicillin-containing LB agar (50 g/ml) over night at 37°C. 
2.3.2.3. Preparation of plasmid DNA  
Plasmid DNA mini-preparation was performed according to the following protocol: a 
single bacterial colony from the LB agar was transferred into 2 ml of LB medium 
containing 50 g/l ampicillin. The tube was incubated over night shaking at 37°C. On 
the next day 1.5 ml of E. coli culture was transferred in a reaction cup and centrifuged for 
30 sec at maximum speed. The pellet was then dispersed in 300 l resuspension buffer P1 
(all buffers from Qiagen, Hilden, Germany). 300 l lysis buffer P2 was added, mixed and 
incubated at room temperature for 5 min. Pre-chilled neutralization buffer P3 was added, 
mixed gently and centrifuged for 15 min at maximal speed. 800 l of supernatant was 
transferred into a new reaction cup. DNA was precipitated by adding 750 l isopropanol 
(Roth, Karlsruhe, Germany) and contents were mixed well and centrifuged for 15 min at 
maximum speed. The pellet was then resuspended in 100 l H2O and again precipated 
by adding ethanol (96 %, Roth Karlsruhe, Germany) and centrifugation for 15 min at 
maximum speed. DNA pellet was air-dried and dissolved in 30 ml TE buffer (pH 8.0). 
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Endofree® plasmid maxi preparation was performed according to manufacturer’s 
protocol (Endofree® Plasmid Maxi kit; Qiagen, Hilden, Germany) for the 
electrophysiology experiments. 
The concentration of DNA was determined by measuring absorbance at 260nm using a 
Nanodrop2000 (Thermo Scientific, Wilmington, USA). The ratio between the absorbance 
values at 260nm and 280nm was taken as a quality control for DNA purity and should 
fall between 1.8 and 2.0. 
2.3.2.4. DNA cloning of calcium channel subunit 2 -1 
In order to generate a mammalian expression vector, the coding sequence of the murine 
2 -1 was subcloned from the pBluescript vector into a pcDSA3 vector. Therefore new 
restriction sides for Kpn I and Not I were introduced via PCR with a Mfe I restriction 
side in the middle of the construct. 
 
Table 2.3:3: Primer used to introduce new restriction sides for subcloning of 2-1 into pcDSA3 vector. 
primer name sequence  
KpnI-2-fwd 5’- ATG GTA CCA TGG CTG CTG GCT GCC TGC -3’ 
2-NotI-rev 5’- ATG CGG CCG CTC ACA GTA GGT AGT GTC TGC -3’ 
2-MfeI-rev 5’- TGG GGT TCT TTG GCT GAA GAT TTG G -3’ 
MfeI-2-fwd 5’- TCG TTT TAC ACT CTG TCC CAA TGG C -3’ 
 
PCR was performed using a master mix containing High fidelity PCR enzyme mix 
(Fermentas, Burlington, Canada) and corresponding buffer, deoxynucleoside 
triphosphate (dNTPs; Fermentas, Burlington, Canada) and the respective primer pairs 
following manufacturer’s recommendations. The PCR cycling protocol was including a 
denaturation step at 95°C for 5 min, a 3-step amplification protocol with 37 cycles of 30 
sec at 95°C, 1 min at 60 °C and 1 min at 72°C and a final prolongation step at 72°C for 5 
min. The PCR amplification products were purified by exercising the DNA bands from 
an agarose gel containing 2 l ethidium bromide stock solution (10 mg/ml; Roth, 
Karlsruhe, Germany) and the use of a GeneJET® gel extraction kit (Fermentas, 
Burlington, Canada).  Digestion of PCR fragments with restriction endonucleases was 
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performed in 3 separate reaction mixtures. The pcDSA3 vector was digested with Not I 
and Kpn I in buffer 2 (10x) and the addition of 0.2 l BSA at 37°C for 1 h. The two PCR 
fragments were cut with either Kpn I and Mfe I in buffer 1 or Not I and Mfe I in buffer 4 
with the addition of BSA at 37°C for 1 h (all enzymes from NEB, Frankfurt, Germany). 
Digested DNA fragments were again purified with the help of an agarose gel and 
GeneJET® gel extraction kit. Purified digested DNA fragment concentrations were 
determined using a Nanodrop2000 and required amounts of DNA fragments were 
calculated in regard to basepairs and molecular weight. Determined amounts were used 
for ligation master mix containing 200 ng of digested vector and 150 ng of each 21 
fragment. With the help of 2.5 units of T4 DNA ligase (Fermentas, Burlington, Canada) 
and corresponding buffer, the three fragments were ligated over night at 16°C to result in 
the insertion of the murine 21-coding sequence in a mammalian expression vector 
pcDSA3. The resulting clones were confirmed by sequencing as described in section 
2.3.3. The cloning was successful, but showed one point mutation containing a cytosin 
instead of a thymin at bp 292. This was corrected by the use of QuikChange II XL site-
directed mutagenesis kit® (Stratagene, Santa Clara, CA, USA) according to 
manufacturer’s protocol. Primers were designed using Stratagene’s web-based 
QuikChange® Primer Design Program (B 1.6) according to the kits guidelines. Resulting 
mutagenesis clone was again sequenced and correctness of the coding sequence of 2 1 
and correct orientation within the vector was confirmed.  
2.3.3. Sequencing of plasmid DNA 
Around 400 ng of plasmid DNA was taken as a template for sequencing. For the PCR 
master mix 0.25 l BigDye ® terminator V1.1 (Applied Biosystems, Foster City, CA, 
USA), 2.25 l 5x BigDye sequencing buffer and 0.25 l primer (10 M) were added. The 
reaction mixture was diluted to 10 l. The PCR cycling program included 32 cycles with 
10 sec denaturation at 96°C, 5 sec annealing at 55°C and a 4 min elongation step. After 
amplification the sequencing was done by the Cologne center for Genomics (University 
of Cologne, Germany) as a service with an Applied Biosystems 3730 DNA analyzer.  
Sequences were analyzed using FinchTV (Geospiza, Seattle, WA, USA) and MacVector 
Assembler (Cambridge, UK).  
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2.3.4. Eukaryotic cell culture  
Native HEK293 (Human Embryonic Kidney) cells were cultured under normal growth 
conditions at 37°C and 6% CO2 in 60 mm polystyrene Petri dishes (Falcon, Heidelberg, 
Germany).  All procedures to cultivate or transfect cells were carried out under a sterile 
laminar flow hood to prevent contamination. Media and PBS were warmed in a water 
bath at 37°C before use.  
 
Table 2.3:4: Solutions for cell culture. 
Cell culture 
medium 
500 ml 1xDulbecco’s modified Eagle medium (DMEM; Gibco, Grand 
Island, USA) 
50 ml fetal calf serum (FCS; PAA, Pasching, Austria) 
2.75 ml antibiotics (100x penicillin-streptomycin solution, PAA) 
PBS 1x Dulbecco’s phosphate-buffered saline (PAA, Pasching Austria) 
Trypsin 1x trypsin-ethylenediaminetetraacetate (EDTA: PAA, Pasching, 
Austria) 
 
Trypsinization was used to detach the adherent cells from the surface of cell dishes for 
passaging. Therefore, the culture medium was carefully aspirated from the cell culture 
dish and cells were gently washed with 4 ml PBS. The cells were incubated with 700 l 
Trypsin-EDTA for 2 minutes at 37 °C. Cells were resuspended in 3 ml fresh medium and 
a fraction of 300-600 l was transferred into new 60 mm dishes and filled up to 4 ml with 
cell culture medium. For subculturing cells were routinely passaged twice a week. 
2.3.5. Transient transfection by non-liposomal reagent 
The examined CaV1.2 channel complexes were expressed in HEK293 cells by using 
transient transfection of the CaV1.2 subunits. The pore forming CaV1.2 subunits CaV1.2exon 
21 (1c-KN) or CaV1.2exon 22 (1c-Cl16 K) were coexpressed with one of the  subunits (2b, 
2d, 3A) and the 2-1 subunit. For all experiments an enhanced green fluorescent protein 
(eGFP) was cotransfected to distinguish the successfully transfected cells. The amounts of 
CaV1.2,  subunit, 21 and eGFP plasmids were 1 g, 0.5 g, 0.75 g and 0.3 g, 
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respectively. The DNA mixture was introduced into the HEK293 cells by Effectene® 
transfection reagent (Qiagen, Hilden, Germany). In brief, HEK293 cells were seeded onto 
60 mm dishes one day before transfection to reach 70-80 % confluency on the day of 
transfection. The DNA mixture (2.55 g) was diluted with the DNA-condensation buffer 
to a total volume of 150 l and 20 l enhancer was added, vortexted and incubated at 
room temperature for 3 minutes. Then, 62.5 l Effectene® was added and samples were 
incubated at room temperature for 10 min to allow transfection complex formation. 
Culture medium was aspirated from seeded cells, cells were washed once with PBS and 
fresh growth medium was added to the cell. The transfection complexe mixture was 
diluted in 1 ml growth medium and added drop wise onto the cells. Cells were 
incubated with transfection complex at 37 °C over night. After incubation, the medium 
containing the complexes was removed and cells were passaged into 35 mm Petri dishes 
for electrophysiology. 
2.3.6. Patch-clamp technique  
The patch-clamp technique was developed by Neher and Sakmann in 1976 to measure 
currents through single acetylcholine-activated channels in cell-attached patches of 
membrane of frog skeletal muscle [103]. Principle of this method is to electrical isolate a 
small part of the membrane by attaching the tip of a glass micropipette. A high resistance 
seal (gigaohm seal, >1GΩ) is achieved by gentle pressing of the tip against the membrane 
of a cell followed by gentle suction through the pipette.   
This gigaohm seal is the requirement for several possible patch-clamp configurations 
(Figure 2.3.3:1): A) cell-attached recordings where the cell membrane stays intact after 
gigaseal formation. Small patch size allows current recordings through a single ion 
channel in the patch. B) inside-out patch made by pulling the membrane patch off the 
cell into the external solution. C) whole-cell recording is achieved by rupturing the 
membrane patch using more suction and the cytoplasm is connected to the pipette 
solution. This configuration is used to investigate the activity of all channels expressed in 
the patched cell. D) Outside-out patch which can arise out of the whole-cell configuration 
by pulling away the pipette isolating the piece of membrane patch and building a convex 
Materials and methods 
- 40 - 
membrane on the end of the pipette. The configuration under A, B and D can be used for 
recording of single-channel activity. 
 
Figure 2.3:1: Diagram illustrating the different patch-clamp configurations (modified from [104]). 
The patch-clamp technique for whole-cell recordings is based on the voltage-clamp 
method described by Hodgkin and Huxley in 1952 [105]. It allows to record the 
transmembrane current and the controlled input is the “clamped” membrane voltage 
applied to the cell examined [106]. It can be applied to small cells and in vivo 
measurements.  
 
 
 
 
 
 
 
 
 
Figure 2.3:2: (A) Simplified circuit of a whole-cell recording: Current im flows in the cell resistance Rc 
and ic in the capacitance.  Pipette current (ip) equals im +ic and flows in the series resistance Rs between 
pipette and cell and produces a voltage error Vp –Vc = ipRs. (B) time course of changes of Vc and ip 
following a step of Vp (adapted from [104]). 
A 
B 
C 
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A B 
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2.3.7. Patch-clamp set up 
Patch-clamp experiments were performed in a Faraday cage to shield the recording 
electrode from external alternating current (AC) fields (fig. 2.3.4:1). The apparatus also 
requires a vibration-cushioned table (Barry controls GmbH, Raunheim, Germany) and 
an inverted fluorescence microscope (Nikon corporation, Japan). The micropipette, 
including the recording electrode, is directed by a hydraulic micromanipulator (MHW-
103, Narishige International, Tokyo, Japan) towards the cell and a headstage preamplifier 
(Gain: x1/10, Axon Instruments, CA, USA) is connecting the electrode and the main 
amplifier (Axopatch 1D, Axon Instruments, CA, USA). Because currents detected in the 
experiments are at the range of pA to nA, specialized amplifiers are used for high-
resolution current recordings.  Recording electrode and bath electrode were coated silver 
wires. For coating, silver wires were cleaned with ethanol and immersed into a 3 M KCL 
solution. The wire was connected to an anode of a direct current voltage source and a 
current of 1 mA was applied until the wire was uniformly blackened. 
 
 
 
 
 
 
 
 
 
 
Figure 2.3:3: Patch-clamp set up: (1) A/D converter (2) patch-clamp amplifier (3) Faraday cage (4) vibration-
cushioned table (5) inverted fluorescence microscope (6) headstage with pipette holder (7) hydraulic 
manipulator 
For preparing the micropipettes, borsilicate glass capillaries (OD/ID: 1.7/1.42 mm, 
Hilgenberg, Malsfeld, Germany) were cut in 72 mm length and pulled into two 
symmetrical micropipettes with a P-97 pipette puller (Sutter instruments, CA, USA). 
Pipettes were prepared on the day of measurement and fire polished using Narishige 
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Microforge (Tokyo, Japan). Pipette resistance was between 1.8 – 3.0 MΩ for whole cell 
recordings. 
2.3.8. Whole-cell recordings 
Whole-cell recordings were obtained 48 - 72 hours after transfection. Prior to recordings, 
cells in 35-mm cultures dishes were washed with freshly prepared external bath solution 
and maintained at room temperature (19-23 °C). The patch pipettes were filled with 
filtered pipette solution (0.2 m injection filter; Braun, Melsungen, Germany) and 
attached to the pipette holder including the recording electrode.  Whole-cell recordings 
were performed by formation of a gigaohm seal of a fluorescence-positive HEK cell by 
gentle suction. A stable gigaohm seal is essential before penetrating the membrane for 
whole-cell channel measurement. The fast capacity transients flanking the 5 mV test 
pulse (figure 2.3.5:1; A) are mainly associated with pipette capacitance to the bath and are 
compensated. The potential of the pipette interior is adapted to the estimated membrane 
potential. Further suction disrupts the small membrane patch building whole-cell 
configuration (C) and the cell interior is in contact with pipette solution.  
 
Figure 2.3:4: The transient currents in a cell-attached record before (A) and after (B) cancellation with Cfast 
and fast. These transient currents are due to (pipette) capacitance. (C) A whole-cell recording showing 
flanking capacity transients due to cell capacitance (modified after [104]). 
C 
B 
A 
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For whole-cell recordings, currents were typically elicited from a holding potential of -80 
mV to various test protocols using Clampex software pClamp 5.5 and an Axopatch 1D 
amplifier (Axon Instruments, Foster City, CA, USA). Data were filtered at 2 kHz and 
digitized at 10 kHz directly onto a personal computer. The experiments were performed 
with barium as the charge carrier to evaluate the voltage-dependent inactivation in the 
absence of calcium-dependent inactivation [107]. For data analysis pClamp 5.5, Origin 
6.0 and Graph pad prism 4 were applied. 
 
External bath solution 
BaCl2 10 mM 
MgCl2 1 mM 
CsCl 65 mM 
TEA-Cl 65 mM 
Glucose 10 mM 
HEPES 10 mM 
pH adjusted to  7.3 with TEA-OH 
 
Internal pipette solution 
CsCl 140 mM 
MgCl2 1 mM 
Mg-ATP 4 mM 
EGTA 10 mM 
HEPES 9 mM 
pH adjusted to 7.3 with CsOH 
 
2.3.8.1. Pulse protocols 
Current-family protocol was used to obtain current-voltage relationships (I/V) of the 
recorded cells. Therefore cells were depolarized from a holding potential of -80 mV to the 
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test pulses (-40 mV to +50 mV) for 150 ms in 10mV steps. Time between single pulses was 
5 sec. 
To determine the current-voltage relationships, peak current amplitude of each test pulse 
was calculated by subtraction of the leak current of every trace from the maximal 
current. The peak current was divided by the respective cell capacitance to obtain the 
current density-voltage relationships. I/V relationship are presented as mean  SEM. To 
determine V 0.5 act and slope factor, I/V curves were fitted by a combined Ohm and 
Boltzmann relation 
IV = Gmax (V-Vrev)/(1+exp[-(V-V 0.5act)/k]) 
Here IV is the current density at voltage V, Gmax is the maximal slope conductance pF-1, 
V0.5act is the half maximal activation voltage, Vrev is the reversal potential, and k is the 
slope factor. 
The extent of inactivation at 150 ms (% inactivation) was calculated by the following 
equation where I 150 ms is a current at the end of the test pulse and I peak the peak 
amplitude: 
% inactivation (150 ms) = 1- (I 150 ms/ I peak) 
The time constant  was obtained by a mono-exponential fit of the slow inactivation 
phase of I/V currents. 
 
Figure 2.3:5 Pulse protocol for voltage current family recording 
-100mV 
-80mV 
+50 mV 
-40 mV 
150 ms  
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A two steps tail current protocol was used to determine the current activation of CaV1.2 
channels. Here, Barium tail currents were recorded at -50 mV following different test 
pulses (between -70mV and +80 mV). The test pulses were repeated every 5 s.  
The cell is forced by these pre-pulses to open an amount of channels in relation to the 
voltage potentials and leading to a voltage-dependent activation. The potential is then 
stepped back to a standardized potential (-50 mV) to determine the activation – the 
electromotive force (EMF) is standardized for all episodes and therefore the different 
currents are caused only by the voltage-dependent activation of the channels. The 
voltage-dependent activation was calculated by determination of the relative amplitude 
of the tail currents (I/Imax) as a function of conditioning potentials. Analysis was 
performed using the Boltzmann function:  
Imax/(1+exp[(V0.5act-V)/kact]) 
where Imax is the maximum tail current, V0.5act  the midpoint of voltage-dependence of 
activation and kact the slope factor. 
 
Figure 2.3:6 Pulse protocol for tail current recordings. 
 
The voltage dependence of current inactivation of the CaV1.2 channel was determined 
using a steady-state inactivation protocol. During the long conditioning prepulse 
equilibrium (= steady state) is set up between open, closed and inactivation state (figure 
2.3.4.1:3). To quantify the part of the channels which are not inactive yet, the cell is 
-80mV 
+80 mV 
-80mV 
-70 mV 
20 ms                         
-50mV 
10ms 
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pulsed to + 10 mV forcing all non-inactive channels to open. The voltage-dependence of 
inactivation was calculated by taking the relative amplitude of the steady-state current 
(G/Gmax) as a function of the test pulses. Data were fitted with the Boltzmann equation. 
 
 
Figure 2.3:7 Diagram of gating transitions of a voltage-dependent calcium channel (adapted from [106]) 
 
 
Figure 2.3:8 Steady-state inactivation protocols. After a 5000ms conditioning pulse a 150 ms test pulse at 
+10mV was applied. The pre-pulses were ranged between -75mV and +5mV in 5mV steps. 
-80mV 
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-100 mV 
-75 mV 
5000 ms 
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3. Results 
3.1. Expression-profiling of L-type calcium channel subunits 
in human arteries 
3.1.1. Characterization of arterial sections for laser capture 
microdissection 
As a first approach of expression-profiling of L-type calcium channel (LTCC) subunits in 
human arteries, vascular smooth muscle cell (VSMC) areas were isolated via laser capture 
microdissection. The subsequent relative quantification via quantitative real time PCR (qRT-
PCR) required a definition of atherosclerotic areas with proliferative vascular smooth 
muscle cells and adjacent control areas. Therefore, immunohistochemical stainings for 
vascular smooth muscle cells (antibody against smooth muscle actin, SMA) and 
proliferation (antibody against Ki 67) were used to classify the different areas within one 
sample. Furthermore, morphology of section accounted for classification. 
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Figure 3.1:1 Representative immunohistochemical patterns of the arterial preparation used for laser 
microdissection of VSMC and isolation of RNA from areas of proliferative smooth muscle cells (A,B) and 
adjacent control areas (C,D) that had no obvious evidence of atherosclerosis. Shown are photo-micrographs 
after staining of serial sections of femoral arteries with antibodies against smooth muscle actin (SMA, A,C) 
and and Ki  67 (B,D), a marker of cellular proliferation.  
The implementation of this differentiation within one sample - between atherosclerotic and 
control areas – revealed difficulties finding both in one sample. The majority of samples 
showed atherosclerotic changes in cell structure in all serial cuts. Areas with no obvious 
evidence of atherosclerosis were rarely found and were then reflected throughout the whole 
sample. Hence the characterization and the following classification were carried out sample 
wise. 
Furthermore the carotid artery samples were showing excessive atherosclerotic changes 
descend right of out of heavy plaques areas. In contrast the femoral artery samples were 
represented by more early stage atherosclerotic changes with origin only close the 
atherosclerotic narrowing due to surgery procedures.  
A 
C 
B 
D 
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3.1.2. Isolation of RNA from microdissected and whole tissue arterial 
samples 
The isolation of sufficient RNA amounts and quality from the microdissected samples 
proved to be challenging. Variation within the method (chapter 2.1.3) still led to poor RNA 
amounts. Testing the method with liver biopsy serial cuts led to suitable RNA amounts and 
quality.  
Having a closer look on RNA quality of the whole-tissue artery samples, some RNA 
samples already show degradation products and low quantity (RIN 5,87, 123 ng/l; Figure 
3.1:2 A) with a validated RNA isolation protocol (as comparison see also Figure 3.2:3). As 
these tissue biopsies were taken within operation procedures, this low quality could be due 
to relatively long time duration until flash freezing in liquid nitrogen or great blood 
amounts containing high amounts of RNases. For further analysis of whole tissue samples, 
only isolated RNA with high quality was used. 
 
 
 
 
 
 
 
Figure 3.1:2 Results of a RNA pico LabChip® of (A) isolated RNA from an exemplary human side-branch of 
the femoral artery (RIN 5, 87, 123 ng/l) with degradation products and (B) exemplary microdissection 
sample with no detectable concentration and quality. The detection minimum of a RNA pico LabChip® is 
going down to 50 pg/µL of total RNA. 
 
 
 
B A 
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3.1.3. Expression-profiling of LTCC subunits in microdissected 
vascular smooth muscle cells 
With the technique of laser capture microdissection, VSMC areas could be isolated from the 
serial section of arteries. Due to problems isolating sufficient RNA amounts (see chapter 
3.1.2) only a few samples could be analyzed with very high Ct values (Ct values around 29-
35). With the help of melting curve analysis at the end of each qRT-PCR one can exclude 
that fluorescence signals arise from contamination or primer dimers and each melting curve 
could be assigned to the specific amplicon.  
 
Table 3.1:1 Expression pattern of LTCC subunits in microdissected samples of human arteries. RNA was 
isolated from microdissected VSMC  areas and analyzed by qRT-PCR with 18S RNA as a reference gene. 
Each column is reflecting one individual sample. The + scale is reflecting the relative mRNA expression 
levels based upon   ct values. No symbol means that expression is not detectable.  
Human microdissection samples 
 Atherosclerotic areas control areas 
 A. carotis A. femoralis A. femoralis 
exon 21     ++++ ++++  
exon 22    ++++ ++++ ++  
1      ++++ ++++ 
2 ++ ++++ ++  ++++ +++  
3      +++  
4      +++  
 
  ct values 
++++ up to 11 
+++ >11 to 13 
++ >13 to 15 
+ >15 to 17 
+ >17 to 19 
+ >19 to 21 
 no signal 
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The qRT-PCR data reveals that both, exon 21 and exon 22, are expressed on mRNA level – 
in atherosclerotic as well as in non-atherosclerotic control VSMC areas. The 2 isoform is the 
only consistently detectable  subunit in the atherosclerotic VSMC areas. In control areas 
from femoral artery samples all four  subunits are detectable with 1 being predominant. 
3.1.4. Expression-profiling of L-type calcium channel subunits in 
whole-tissue samples of human arteries 
Since the isolation of sufficient amounts of RNA from the microdissected VSMC was 
problematic, whole arterial biopsy samples were analyzed as well. The examination of the 
expression-profile of LTCC subunits in atherosclerotic and non-atherosclerotic whole-tissue 
samples required a control group for relative quantification using qRT-PCR and the ct 
analysis. Samples of patients undergoing stent surgery or amputations due to non-
atherosclerotic reasons (e.g. traumatic rupture of arteries) are rare and therefore a problem 
to serve as control group. In this study, 2 of such samples were collected over the year and 
taken as a first idea of a control group.  
 
Table 3.1:2 Expression-pattern of LTCC subunits in whole-tissue samples of human arteries. RNA was 
isolated from whole tissue samples and analyzed via qRT-PCR. Taking 18S RNA as a reference gene, + scale 
is reflecting relative mRNA expression levels based upon  ct values. 
 
 
Human arteries – whole tissue samples 
 Atherosclerotic samples Control  
sample A. carotis A. femoralis - branch A. femoralis A. femoralis 
exon 21 + + + + ++++ ++++ + + ++ ++ ++ 
exon 22 + + + + ++ ++ + + + + + 
1 + + + ++ +++ ++++ + + + ++ + 
2 + + + ++ +++ ++++ + + + ++ + 
3 + + + + ++ +++ + + + + + 
4 +  + ++ ++ +++ + + + + + 
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  Ct values 
++++ up to 11 
+++ >11 to 13 
++ >13 to 15 
+ >15 to 17 
+ >17 to 19 
+ >19 to 21 
 no signal 
 
The results of the ct analysis of whole-tissue samples reinforce the finding that exon 21- as 
well as exon 22-containing Cav1.2 subunit is expressed on mRNA level. The exon 21 
containing CaV1.2 seems to be the predominant splice variant. The mRNA of all four  
subunits can be found in human arteries, 1 and 2 seem to be more abundant then 3 and 
4.  
Looking at the expression profile of each sample, inter-individual differences are clearly 
seen. Also differences between the diverse sources of sample-taking are represented in the 
variation of data. Due to the variability between the samples of different origin and 
assumed differences in stage of atherosclerosis, the comparative Ct analysis was only 
possible between the atherosclerotic and non-atherosclerotic femoral artery samples. 
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Figure 3.1:3 Expression-profiling of LTCC subunits in atherosclerotic (n=7) and non-atherosclerotic (n=2) 
femoral artery whole-tissue samples. Relative expression comparing the two groups is given as- Ct values 
using S18 rRNA as a reference gene. Data is shown as “box and whisker” plots (median, 1st and 3rd quartile, 
minimum and maximum). The median of all LTCC subunit mRNA level is decreased in comparison to the 
atherosclerotic samples. The analysis also displays the high diversity of results. 
TheCt analysis supports the findings above, both exon 21 and exon 22 are expressed with 
exon 21 being predominant spliced exon in the femoral artery samples (data not shown 
here). All 4  subunits are expressed looking at the whole tissue samples. The relative 
expression, comparing atherosclerotic and non-atherosclerotic samples, displays a slight 
decrease in LTCC subunit expression on mRNA level in atherosclerotic samples. 
3.1.5. Absolute quantification of exon 21 and exon 22 using oligo 
standards  
Since it was difficult to find non-atherosclerotic control samples or control VSMC areas, an 
attempt was to establish standards for absolute quantification via qRT-PCR. There were no 
validated results for absolute quantification using plasmids as calibrator. Calculation of the 
copy number led to inexact results and the Ct values were ceiling at around a cycle number 
of 30 due to carryover of plasmids in the low concentration range. 
An accurate way of absolute quantification is the use of synthesized oligonucleotides of the 
specific amplicons plus small overhang. However, they cannot be synthesized easily when 
size of the amplicon exceed 120 bp due to an increasing error rate. Therefore, the amplicons 
of primer pairs of exon 21 and exon 22 where chosen to evaluate the standards for absolute 
quantification. 
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Figure 3.1:4 Standard curves for determination of concentration of the sample of interest. The Ct values are 
drawn against the log 2 copy number of oligonucleotide standard. At Ct values around 32 (exon 22) or 34 
(exon 21) determined values are showing a ceiling effect. 
The standard curves are also changing their slope factor at around Ct values of 32 (exon 22) 
and 34 (exon 21). Above these ct values, thus at low copy numbers, the method is not 
suitable. 
3.2. Expression-profiling of L-type calcium channel subunits 
in an atherosclerotic mouse model 
3.2.1. Development of atherosclerosis in apoE -/- mice 
ApoE -/- mice, fed with a western-type diet, develop up to stage V lesions with increasing 
age [98]. As shown in Figure 3.2:1, the chosen age groups of apoE -/- mice, fed with western-
type diet, represent different stages of atherosclerosis. The sections at the height of the aortic 
sinus show clearly a development of increasing lesion areas with age (74.39 ±13.11 vs. 143.6 
± 6.12 vs. 204.6 ± 14.26 x 1000 m2 given as mean + SEM). The control apoE -/- mice at the age 
of 12-14 weeks, fed with normal diet, show only small or no atherosclerotic plaques (picture 
not shown; 5.86 ± 3.4 x 1000 m2). Wildtype C57/Bl6 mice, which were chosen as a healthy 
control, do not show a development of atherosclerotic plaques. Even those fed with a 
western-type diet over 8-10 weeks are not showing the development of atherosclerotic 
lesions (picture not shown). 
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Figure 3.2:1 Toluidin-blue staining of the aortal cross-sections at the height of the aortic sinus of the animals 
used in this study. Development of atherosclerosis is seen with increasing age of the apoE -/- mice all fed 
with western-type diet. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2:2 Graph is showing quantification of atherosclerotic lesion size at the aortic sinus. The progression 
of atherosclerosis is seen in the increasing lesion area with increasing age of the apoE -/- mice (74.39 ± 13.11 
vs. 143.6 ± 6.12 vs. 204.6 ±14.26 x 1000 m2 given as mean ± SEM ). Control apoE -/- mice fed with a normal diet 
developed only small lesion areas at the age of 12-14 weeks (5.86 ± 3.4 x 1000 m2). Values are given as lesion 
area (x1000 mm2) as a scatter dot-plot with mean. 
In the following mRNA expression studies all apoE -/- mice investigated were fed with a 
western-type diet from the age of 5 weeks. All wildtype mice were fed with a normal diet.  
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3.2.2. Quality of the isolated RNA 
The quality of RNA is essential for quantitative real-time PCR. Poor RNA quality leads to 
an impairment of data quality [108]. As a quality control with respect to degradation and 
contamination the results of the RNA pico LabChip® were taken. Results show that the 
method used to isolate RNA is suitable to result in high quality RNA. All samples showed a 
RIN value between 8.5 and 9.5 which is a proof for high integrity [109]. The ratios of 28S/18S 
lay between 1.8 and 2.0. 
 
  
 
 
 
 
 
 
 
 
Figure 3.2:3 Results of a RNA pico LabChip® of murine aortic tissue samples. Result overview showing 
RNA gel electrophoresis and an exemplary electropherogramm summary including RIN, concentration and 
rRNA ratio. 
3.2.3. Real-time PCR analysis of L-type calcium channel subunits in 
murine aorta  
The mRNA expression level of LTCC subunits was determined in the aortic arch of 
wildtype and apoE -/- mice using quantitative real-time PCR (qRT-PCR). Different age 
groups were chosen to represent the progression of atherosclerosis over time.  
Transcripts of all three  subunit isoforms investigated were present at different expression 
levels in all animals. 2 and 3 are the predominant  subunits in the aorta whereas 1 shows 
only low expression on mRNA level. In apoE-/- mice as well as in wildtype mice both exon 
21- and exon 22-containing Cav1.2 subunit mRNA were found. The exon 22-containing 
splice variant of the pore-forming CaV1.2 is more abundant. In older apoE -/- mice the ratio 
of exon 21- exon 22 is significantly changing (12-14 weeks old 0.409 ± 0.038 vs. 16-18 weeks 
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old 0.613 ± 0.107; p=0.0422). The mRNA amount of exon 22 is decreasing whereas exon 21 is 
staying at the same level (Figure 3.2:4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2:4 Expression-pattern of the LTCC subunits of wt (A,C)  and (B) apoE -/- (B,D,E) mice at the 
different stages of atherosclerosis. The mRNA expression is given as 2-ct values using S29 as a reference 
gene. The top row is showing wt and apoE -/- mice at  the age of 12-14 weeks (A,B), the middle row the age 
group of 16-18 weeks (C,D) and the bottom row is representing apoE -/- mice at the age of 22 weeks (F). 2-ct 
values are shown as geometrical mean + SEM. 
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Relative quantification was used to detect any changes of LTCC isoform expression in 
between apoE -/- and wildtype or in between further progression of atherosclerosis in older 
apoE -/- animals. The ct values show a transient increase of LTCC subunits in apoE -/- 
mice compared to wt mice at the age of 12-14 weeks. 1 and 3 are significantly increased (p= 
0.0391 and p=0.0217). With increasing age and stage of atherosclerosis LTCC subunits are 
decreasing (see Figure 3.2:5 B and C) compared to 12-14 week old apoE -/- mice. In contrast, 
the wt mice do not show a change in mRNA levels with increasing age (Figure 3.2:5 D). At 
the age of 16-18 weeks 1, 2 and 1c as well as exon 22 are significantly decreased. In an 
advanced stage of atherosclerosis at the age of 22 weeks the apoE -/- mice show still a 
decrease of LTCC subunits on mRNA level compared to 12-14 week old animals but no 
further decrease compared to 16-18 week old apoE -/-. There is no clear-cut switch of LTCC 
subunit expression within the development of murine atherosclerosis. 
  
 
 
  
  
 
 
 
 
 
  
 
 
 
 
Figure 3.2:5 Relative expression of LTCC subunits, given as 2 –ct values , of (A) Apo e-/- mice compared to 
wt mice at the age of 12-14 weeks. (B) is showing 16-18 week old apoE -/- mice compared to 12-14 week old 
apoE -/- mice and (C) 22 week old ApoE -/- compared to 12-14 week old apoE -/- mice. (D) 2 –ct values of 16-
18 week old wt mice compared to 12-14 week old wt mice. Data is shown as “box and whisker” plots 
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* * * 
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(median, 1st and 3rd quartile, minimum and maximum). Significant differences are marked by *p<0.05 
(Student’s t-test of  ct values).  
3.2.4. Qualitative detection of exon 21 and exon 22 in the murine aorta 
As a confirmation that both alternatively spliced exons 21 and 22 are present, a qualitative 
PCR method was exercised. Reverse transcriptase-PCR (RT-PCR) with primers spanning 
exon 18 to 27 of the pore forming CaV1.2 followed by Avr II digestion clearly display that 
both exons are present in wt and in apo E -/- mice. The single band at the level of 913 bp 
stands for the undigested exon 21 whereas exon 22 is digested by Avr II and is represented 
by the two bands at the height of 542 and 371 bp. There is no sign for an exon switch in 
atherosclerotic aortic tissue. 
 
Figure 3.2:6: Qualitative analysis of the alternative spliced variants of the pore-forming CaV1.2 containing 
either exon 21 or exon 22. RT-PCR was carried out using primers spanning exon 18 to 27 followed by analytic 
digestion with Avr II.  The band at the height of 913 bp represents undigested exon 21-containing isoforms 
whereas the bands at 542 bp and 371 bp are products of the digested exon 22. 
3.2.5. Expression-profiling of the 2 isoforms in murine aorta 
The finding of 2 as one of the predominant  subunits in the aortic samples led to further 
investigation. To get an insight into predominant2 isoforms expressed in the murine aorta, 
specific primers for qRT-PCR were designed. To insure that they only detect the demanded 
2 isoform, small amounts of plasmids were used as specific templates for qRT PCR. Tests 
show that the primers used in this study only detect the specific isoform and none of the 
other 2 isoforms.  
 
913 BP 
 
18 - 20 21 23 - 27 22 
Avr II 
371 BP 542 BP 
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Figure 3.2:7 qRT PCR testing the specifity of the used primer pairs for the individual  isoform.  The 2d (b2d) 
primer assay only detects 2 N1 (2d), whereas the 2e primer shows affinity only for the 2 N5 plasmid 
(nomenclature s. material and methods). Sample 8 to 12 display the comparable efficiencies of the 2 common 
primer for all 2 isoforms.  
Theanalysis via qRT-PCR shows that 2d is the main 2 isoform expressed on mRNA level 
in aortic tissue of both apoE -/- and wt mice (2-ct values: 37.74 ± 12.06 and 25.95 ± 6.95). Only 
small expression levels of 2b and 2a subunit isoforms were detected (wt 2-ct values:  7.53 ± 
1.96 and 5.14 ± 1.97; apoE -/- 2-ct values: 5.12 ± 3.39 and 2.11 ± 0.85), 2e was barely 
detectable.  
 
 
 
 
 
 
 
 
Figure 3.2:8  Expression pattern of subunit isoforms on mRNA level. Data is given as 2 - 
 ct
 values with S29 
as a reference gene. The graphs are representing the exemplary results of qRT-PCR of 16-18 week  old (A) wt 
and (B) Apo E -/- mice. 2d is the predominant 2 isoform in murine aortic tissue in wt and apoE -/- mice. 2-ct 
values are shown as geometrical mean + SEM. 
Evaluating the expression level of 2 isoforms in context of the development of 
atherosclerosis displays also a transient increase of 2d, 2b and 2a isoforms at early stages of 
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atherosclerosis. Comparing 12-14 weeks old apoE -/- mice and wt mice at the same age 
revealed a significant increase in 2d (p= 0.0087) as the predominant 2 isoform. In later 
stages of atherosclerosis the 2 isoforms also reflect the decrease of LTCC subunits as 
described above.   
 
 
 
 
 
 
 
 
Figure 3.2:9  Relative expression of 2 subunit isoforms , given as 2 –ct values , of (A) 12-14 week old apoE -/- 
mice compared to  wt  mice at the same age.  Graph (B) is representing 16-18 week old apoE -/- mice 
compared to wt mice at the same age. Data is shown as “box and whisker” plots (median, 1st and 3rd quartile, 
minimum and maximum). Significant differences are marked by *p<0.05 (Student’s t-test of ct values).  
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3.3. Functional studies of murine L-type calcium channels  
3.3.1. Current density-voltage relationships  
To investigate the functional impact of the different  subunit isoforms on the exon 21 
(CaV1.2 ex21) and exon 22 (CaV1.2 ex22) containing splice variants of the CaV1.2 pore-forming 
subunit, whole-cell currents were measured as described in chapter 2.3.8. The two splice 
variant of CaV1.2 where coexpressed with 2-1 and either 2b, 2d or 3A in HEK293 cells. 
 
  
Figure 3.3:1 (A) Current density-voltage relationships obtained from CaV1.2 channels containing either exon 
21 or exon 22 coexpressed with 2b and 2-1 subunits. The maximum current density of the exon 22-
containing CaV1.2 subunit is significantly enhanced compared to the exon 21-containing isoform (-94.63 ± 
11.90 pA/pF, n=12 vs. -38.05 ± 9.72 pA/pF, n=7) and shifted to the left. (B) I/V relationships of CaV1.2ex 21 or 
CaV1.2ex 22 coexpressed with 2d and an 2-1 subunit. The maximum current density is significantly 
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increased with the CaV1.2ex 21 isoform compared to channel complex containing CaV1.2ex 22(-87.03 ± 7.62 
pA/pF, n=12 vs. -58.00 ±5.99 pA/pF, n=12). (C) Current density-voltage relationships obtained from either 
CaV1.2 ex21 or CaV1.2 ex22 containing channel complexes coexpressed with 3A and 2-1 subunits. The 
maximum current density is enhanced when the exon 21-containing CaV1.2 is coexpressed (-48.55 ± 8.14 
pA/pF, n=8 vs. -31.83 ± 4.41, n=8). (D) Representative whole-cell Ba2+-currents of CaV1.2-exon 21 (1c-KN) or 
CaV1.2-exon 22 (1c-Cl16K) with 2b and 2-1 subunit coexpression in HEK293 cells. Exemplary traces were 
obtained by depolarizing from a holding potential of -80 mV to voltages ranging from -20 mV to +30 mV in 
10 mV steps (pulse duration 150 ms).  (E) Mean peak current density given as mean + SEM. Significant 
differences are marked by *p<0.05 (Student’s t-test of I peak).  
The I/V relationships (Figure 3.3:1) uncover the functional relevance of the exon shift of 
CaV1.2 in combination with different subunits. Coexpressing CaV1.2ex22 with 2b, 
maximum current densities are significantly enhanced compared to the exon 21-containing 
isoform of CaV1.2 (-94.63 ± 11.90 pA/pF, n=12 vs. -38.05 ± 9.72 pA/pF, n=7; p=0.0019). In 
addition, peak current density is shifted to the left to more hyperpolarizing potentials by 
coexpression of 2b with CaV1.2ex22. The 3A subunit is triggering the opposite effect: peak 
current density is significantly decreased when coexpressed with CaV1.2ex22 (-31.83 ± 4.41 
pA/pF, n=8 vs. -48.55 ± 8.14 pA/pF, n=8; p=0.015). Interestingly, also the coexpression of 2d 
leads to a significantly decreased maximum of current density with the exon 22-containing 
isoform of CaV1.2 (-58.00 ± 5.99 pA/pF, n=12 vs. -87.03 ± 7.62 pA/pF, n=12;p=0.0067).  
 
Table 3.3:1 Voltage of half-maximum activation (V0.5 act) as determined from I/V relationships of the channel 
complexes 
 2b V0.5 act SEM Slope SEM n 
exon 21 (1C KN) -9.54 2.82 6.22 0.66 5 
exon 22 (1C Cl16K) -23.03 2.07 3.63 0.45 8 
 
 2d V0.5 act SEM Slope SEM n 
exon 21 (1C KN) -16.55 1.15 3.56 0.5 12 
exon 22 (1C Cl16K) -14.93 2.29 4.59 0.41 11 
 
 3A V0.5 act SEM Slope SEM n 
exon 21 (1CKN) -7.33 1.84 6.00 0.33 8 
exon 22 (1CCl16K) -8.89 1.7 6.31 0.56 7 
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Figure 3.3:2 Exemplary Boltzmann-Ohm fittings of current density of CaV1.2ex21 and CaV1.2 ex22 coexpressed 
with 2d as described in chapter 2.3.8.  
A closer look on activation kinetics reveals also a significantly modulation of voltage-
dependence of half-maximum activation (V0.5 act) by Cav1.2ex22 when coexpressed with 2b: 
the V0.5act is shifted to more negative potentials and shows a lower slope factor (Table 3.3:1).  
The other  subunit isoforms do not lead to significantly changes in activation kinetics of the 
channel complexes. 
3.3.2. Time- and voltage-dependent inactivation 
To investigate whether inactivation kinetics account for the differences found in the I/V 
relationships, time- and voltage-dependent inactivation were analyzed. Therefore, the 
percentage of current that has inactivated after 150 ms of depolarization (% inactivation) 
and the time constant of inactivation for current decay () were determined [110]. 
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Figure 3.3:3 Voltage- and time-dependent inactivation: Voltage-dependence of the inactivation rate 
(determined as the fraction of peak current inactivated after 150 ms of depolarization) of (A) 2b co-
expressed with either CaV1.2 ex21 (n=7) or CaV1.2 ex22 (n=12) (B) 2d coexpressed with either CaV1.2 exon 21 
(n=8) or CaV1.2 ex22  and (C) 3A coexpressed with either CaV1.2 ex21 (n=8) or CaV1.2 ex22 (n=8). (D,E,F)  Co-
responding inactivation rates indicated by the time constant for inactivation for current decay obtained by 
mono-exponential fits of the raw data. All data is given as mean ± SEM.  Significant differences are marked 
by *p<0.05 (Student’s t-test). 
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Examining the voltage-dependence of inactivation, channel inactivation was faster and the 
extent of inactivation was nearly complete with 2b being coexpressed with Cav1.2ex22 
compared to cotransfection with CaV1.2ex21. The other channel complex pairs do not show 
significant differences. Comparison of characteristics of inactivation time constant (Figure 
3.3:3: D,E and F) revealed no major changes between exon 21- and exon 22-containing 
Cav1.2 coexpressed with the respective  subunit. Hence they are not responsible for the 
basal current density differences observed in chapter 3.3.1. In addition, steady-state 
inactivation was not affected by the exon 21 - exon 22 shift in channel complexes containing 
either 2b or 2d. In the case of 3A, the half-maximum inactivation potential (V 0.5inact) was 
shifted to more positive potentials when coexpressed with CaV1.2 exon 22. However, 
number of experiments that could be analyzed in this respect were only n=4 for CaV1.2ex22 
and n=2 for CaV1.2ex21. 
 
Table 3.3:2 Steady-state inactivation properties of the characterized CaV1.2 channels following the pulse 
protocol described in chapter 2.3.8. Data was fitted using the Boltzmann equation, the half-inactivation 
potentials (V 0.5 inact) and slope factors were obtained from these fits. 
 
 
 
 
2b + V 0.5 inact SEM Slope  SEM n 
exon 21 (1c-KN) -37,93 2,97 7,43 0,51 5 
exon 22 (1c-Cl16K) -39,14 3,29 6,43 1,55 5 
2d + V 0.5 inact SEM Slope  SEM n 
exon 21 (1c-KN) -36,95 1,04 5,36 0,36 8 
exon 22 (1c-Cl16K) -34,73 1,19 5,28 0,5 9 
3A + V 0.5 inact SEM Slope  SEM n 
exon 21 (1c-KN) -35.14 1.48 6.08 0.26 2 
exon 22 (1c-Cl16K) -27.86 0.36 3.46 0.92 4 
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Figure 3.3:4 Steady -state inactivation curves of 2d fitted with a Boltzmann equation described in chapter 
2.3.8. No significant difference is found in the inactivation kinetics coexpressing either CaV1.2 ex 21 or       
CaV1.2 ex 22.  
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4. Discussion 
4.1. Expression profiling of human L-type calcium channel 
subunits 
Voltage-gated calcium channels play an important role in the elasticity and contractility of 
arterial smooth muscle cells. The contraction of VSMC is triggered by calcium influx 
through LTCCs [111]. In addition, an increase of cytosolic intracellular calcium is needed for 
proliferation of VSMC [38]. An exon splice shift in the pore-forming subunit of LTCCs, as 
described by Tiwari et al. in the development of human atherosclerotic lesions [91], is an 
important finding as alternative splicing can lead to differential pharmacological and 
biophysical properties of the channel [60-62, 91, 112]. Earlier functional studies showed that 
these two splice variants of CaV1.2 lead to differential electrophysiological properties in the 
context of different  subunits in HEK293 cells (see chapter 1.3). Therefore, this study 
intended to examine the expression pattern of auxiliary  subunits in human atherosclerotic 
and non-effected tissue to link the functional data with characteristically features of VSMC 
in the development of atherosclerosis. Elucidation of the channel composition can lead to 
further understanding of mechanism underlying the observed phenotypic changes of 
VSMC in the development of atherosclerosis. 
Reproducing the methods described in the work of Tiwari et al. to insure comparability led 
to several problems. The theory of finding unaffected as well as atherosclerotic areas in one 
biopsy turned out to be not practicable. Remodeling of the arterial wall was found in either 
all or none of the serial cuts of a sample. Therefore no direct comparison of affected and 
unaffected areas within one sample as published was possible. Hence a direct control group 
was not available for qRT-PCR analysis and samples from different individuals were 
compared. This method is implicating a risk to detect not only gene expression differences 
due to the development of atherosclerosis but also potentially adds a factor of inter-
individual differences between patients. This diversity in patient data can include 
environmental factors and genetics [113].  
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Furthermore, the isolation of sufficient RNA amounts and quality from the microdissected 
VSMC areas proved to be very difficult. Hence, analyzable sample number was low and 
statistical power of the data was small. Taken this as restrictions of the method, the results 
confirm the predominant  subunit - 2 is consistently found in all analyzed sample, which 
is conform to earlier findings identifying 3 and 2 as predominant  subunits in VSMC 
[92]. There is no differential expression pattern of subunits found in microdissected VSMC 
areas from healthy and diseased samples.  Surprisingly, both exon 21 and exon 22 are 
detected in atherosclerotic and control areas from femoral arteries. But as described above, 
small number of samples with sufficient RNA quantity and quality result in low statistical 
power. Furthermore, RNA amounts were close to detection limit of qRT-PCR, which was 
determined by standard curves linking copy numbers and ct values.  
Due to these problems, mRNA from whole tissue samples was analyzed. With this method 
also all other cell types in atherosclerotic and non-atherosclerotic arteries are taken into 
analysis. Hence, detected changes in gene expression level may also reflect the changed 
composition of the vessel wall during atherosclerosis, implicating also the presence of 
different cell types [113]. Previous studies, analyzing the expression pattern of LTCC 
subunits in animal models, also investigated whole-tissue arterial samples, hence leading to 
a good comparability [92, 114, 115]. No reference gene was found to correlate with the 
VSMC amount in the analyzed samples. To correct for VSMC number, the marker must be 
stably expressed in all states of atherosclerotic development. But due to remodeling of SMC, 
all eligible SMC-marker were demonstrated to exhibit differential expression in 
atherosclerosis [116, 117]. By comparing the rare control samples with diseased samples 
from the same area of the femoral artery for relative quantification via qRT-PCR, we could 
at least reduce the high variability in gene expression resulting from different sample taking 
sites [113].  
The results reinforce the finding that exon 21- and exon 22- containing splice variants of the 
CaV1.2 subunit are expressed on mRNA level. Exon 21 is the predominantly expressed exon 
in human atherosclerotic and non-atherosclerotic arteries. This finding does not confirm the 
findings from Tiwari et al. in 2006. Looking at  subunit expression, all 4 subunit isoforms 
are found on mRNA level. 1 and 2 isoforms are more abundant then 3 and 4. The 
control samples show the same expression pattern. Published data suggests 2 and 3 as 
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predominant isoforms but no 1; however these results arise only from aortic tissue from 
mice [92], rabbit [114] or bovine aortas [115]. In human aortic tissue it was shown that 3 is 
expressed, but not if this is the predominant  isoform [118].  The detection of 4 is not 
described in arterial tissue so far, but could be due to the presence of nerve endings 
containing 4 [71]. 
Comparing the atherosclerotic and control femoral samples for relative quantification, a 
slight decrease of all LTCC subunits is shown but no expression shift.  Gollasch et al. 
already observed a similar down-regulation of the CaV1.2 pore forming subunit in cultured 
dedifferentiated rat aortic A7r5 cells; it was also shown that expression strongly depends on 
the state of differentiation of VSMCs [44], which is also reflected in this study by the high 
variation in gene expression of LTCC subunits in the individual human samples.  
Taken together, the two approaches used in this study revealed the 2 subunit as the 
consistently expressed  subunit in both atherosclerotic and non-atherosclerotic arterial 
tissue. No splice shift could be observed for the alternatively spliced exons 21/22 of the pore 
forming Cav1.2 subunit. Linking this finding with the functional data derived from 
electrophysiological studies of the human channel complexes, resulting channels containing 
the 2 subunit would lead to enhanced current densities with CaV1.2ex22. This would 
implicate a decreased expression of LTCC as a mechanism for the observed loss of 
contractility in VSMC rather than a splice shift of LTCC subunits. Combination of the two 
expressed CaV1.2 isoform containing either exon 21 or exon 22 with different subunits 
could lead to a mechanism for fine-tuning cell function.  
4.2. The exact stage of atherosclerosis is a critical determinant 
of pathological LTCC remodeling 
The apoE -/- mouse is a well-established model for gaining insights into the pathogenesis of 
atherosclerosis [98, 113]. This model contributes the controllable and standardized 
background needed to interpret the findings in human arterial samples [119]. The two 
different splice variants of CaV1.2 containing either exon 21 or exon 22 are conserved across 
several species (Figure 4.2:1).  
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Figure 4.2:1 Amino acid sequence alignment of alternative spliced exon 21 and exon 22 of CaV1.2 in different 
species. 
The quantification of the lesion size in the aortic root confirmed that the different age 
groups of apoE -/- mice investigated represent standardized groups of different stages of 
atherosclerosis. Environmental factors and inter-individual differences are excluded with 
this approach. 
Here, 3 and 2 are the predominant isoforms of  subunits in atherosclerotic and non-
atherosclerotic aortic tissue. Murakami and colleagues already discovered this expression 
pattern in aortic tissue from wildtype mice. Furthermore, experiments in 3-knockout (3 -/-
) mice revealed a reduced expression of the CaV1.2 subunit in the plasma membrane and a 
30 % reduction in Ca2+ channel current density [92]. Additional functional expression of the 
2 subunit as a predominant  subunit in VSMC would explain why VSMC are still 
functional in 3 -/- mice. Adding to these findings, this study clarifies that there is no 
differential expression, i.e. no prominent shift in the predominant  subunit in the 
development of atherosclerosis. 
Since the different splice variants of 2 are known to modulate LTCC in a different manner 
[80], the expression of the different splice variants was examined. The 2d splice variant 
proved to be the predominant splice variant of 2 subunits in atherosclerotic and non-
atherosclerotic aortic tissue. This is a new finding and important for functional analysis of 
the channel complexes.  Furthermore, in murine aorta both exon 21- and exon 22-containing 
splice variants of CaV1.2 are expressed. No splice shift in between these exons is observed in 
atherosclerosis, which confirms the findings in human arterial tissue in this study.  The exon 
22-containing isoform of CaV1.2 is more abundant in aortic tissue from wildtype and apoE-/- 
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mice. This finding is surprising since the predominant isoform of CaV1.2 in rat aorta 
contains exon 21 [120] and also the human data suggest exon 21 as the predominantly 
expressed exon. This finding should be recognized for transferring data from mouse models 
to the human level. The alternatively spliced exons lead to voltage-dependent 
conformational changes of the channel, which affect DHP binding. The exon 21-containing 
CaV1.2 isoform reveals a reduced sensitivity to DHPs [112]; a splice shift could therefore 
influence therapy with DHPs. Hence the knowledge about the predominant splice variant 
could be beneficial in future individualized therapy of atherosclerosis. DHPs are potent 
antihypertensive drugs and additionally nifedipin as a representative was shown to reduce 
proliferation in VSMCs [40, 121, 122].  
By quantifying the lesion area in the aortic root, this study clearly shows that the chosen age 
groups represent different stages of atherosclerosis and can represent the progression of the 
disease. Therefore, comparing the different age groups of apoE -/- is providing insights into 
molecular changes of LTCC in the progression of atherosclerosis. As described above, no 
splice shift was observed in  subunits or the alternative spliced exon 21/22. Nevertheless, 
the expression level of LTCC subunits changed in the different stages of atherosclerosis. An 
initial increase of all LTCC subunits on mRNA level at the age of 12-14 weeks is followed by 
a significant decrease at the age of 16-18 weeks. This indicates that the exact stage of 
atherosclerosis is a critical determinant of pathological LTCC remodeling. The age group of 
22 weeks is also showing a decrease of all channel subunits, but not at a significant level 
which could be due to low animal number at this group. The expression levels in more 
advanced stages of atherosclerosis correlates with those in the human atherosclerotic 
samples; the stage of atherosclerosis in the aortic arch of the older apoE  -/- mice closely 
reflects the human state of atherosclerosis found in the bypass biopsies [1].  The temporary 
up-regulation of the LTCC subunits at earlier stages of atherosclerosis (12-14 week old apoE 
-/-) on mRNA level could be reflecting a compensation mechanism for decreasing 
functionality of atherosclerotic VSMC.  The strong dependence of expression levels of LTCC 
on the exact stage of atherosclerosis explains why examined human expression level show 
high variability. The serial aortic cuts reveal high variation in the stage of atherosclerosis in 
the different biopsies of patient undergoing stent surgery. Therefore, the human sample 
collection represents different stages of atherosclerosis as well as differential environmental 
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factors. A classification of the human samples into different stages of atherosclerosis would 
help to unravel this issue but would also require a huge number of human samples and 
clear definitions of stages.  
4.3. Modulation of murine L-type Ca2+-channel currents by 
the exon 21/exon 22 splice shift of CaV1.2 
The function of voltage-gated calcium channels has major impact on the contractility of 
VSMC. The influx of external calcium (Ca2+) regulates intracellular free Ca2+ - thereby 
arterial tone - and is important for additional biological processes inside the cell. An 
increase of cytosolic intracellular Ca2+ is for example needed for proliferation of VSMC [38].  
Our group could show several times that  subunit isoforms and their splice variants have 
unique influence on channel-gating and expression of the channel complex in the 
membrane [80-82]. Recently, an effect on whole-cell currents could be shown for the human 
channel complexes containing either the CaV1.2 ex 21 or CaV1.2ex 22 subunit (see chapter 1.3). In 
the context of different subunits (2b and 3a), strikingly different effects were observed 
on whole-cell currents of LTCC. 
In the investigated murine channel complexes, the combination with different  subunit 
isoforms reinforces the functional relevance of the exon 21/exon 22 splice shift. The effect of 
the 2b and 3a subunits on the two splice variants of CaV1.2 is comparable to the evaluated 
human channel complexes in whole-cell measurements. The channel complexes containing 
3A lead to a significantly reduced current density together with the exon 22-containing 
CaV1.2. In contrast, channel complexes containing 2b lead to an increased current density 
together with a shift of peak current density towards more hyperpolarizing potentials with 
the exon 22-containing CaV1.2. This leftward shift is also represented in the activation 
kinetics. The investigation of the time-dependent inactivation – determined as time constant 
 did not reveal significant differences in between the CaV1.2ex21 and CaV1.2ex22 in 
combination with the different subunits. Hence, they do not explain the differential effects 
of  subunits found in the I/V relationships.  
The group around Tiwari already published preliminary data coexpressing CaV1.2ex21 and 
CaV1.2ex22 with a 2a subunit in Xenopus oocytes. These channel complexes feature a faster 
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recovery from inactivation with CaV1.2ex22 and a shift of the channel activation curve to 
more negative potentials, already indicating a  subunit dependent effect on the 
exon21/exon22 splice shift [91]. In previous studies, it has also been shown that different  
subunit isoforms reveal diverse effects on L-type Ca2+ channel currents [57, 123, 124]. In a 
study from 2002, Colecraft and colleagues found distinctive effects of  subunit isoforms on 
channel inactivation kinetics and on the degree of enhancement of whole-cell current 
density. GFP-fused  subunits were overexpressed in cultured adult rat heart cells and led 
to an enhancement of current density with a rank order of 2≈4>1b>3. Furthermore  
subunits uniquely altered the rate of current inactivation. 2a and 4 markedly reduced 
rates of inactivation compared with control whereas inactivation was not significantly 
altered with 1b and 3 [79]. 
Surprisingly, in this study 2d showed qualitatively the same effect on current density as 
3A. Maximum peak current densities are significantly enhanced with the exon 21-
containing CaV1.2. This is in contrast with the expectation of a similar effect on the CaV1.2 
splice variants by 2b since these splice variants of 2 share more structure homology. 
However, they differ by the length of their N-terminus: 2b has a shorter N-terminus 
compared to 2d which was shown to lead to increased open probability, availability, and 
peak current in single channel measurements [80]. On whole-cell level in recombinant 
human channel complexes, 2b and 2d exhibit comparable fast inactivation kinetics, in 
contrast to 2a and 2e which showed slower channel inactivation kinetics and a smaller 
fraction of channels recovering from inactivation with fast kinetics [125]. In recombinant 
murine channel complexes containing a heart specific isoform of CaV1.2 with a short N-
terminus, 2d had a significant effect on steady state activation compared to the other 2 
splice variants - the midpoint of activation of normalized I/V curves was shifted to more 
depolarizing potentials. Furthermore, 2d and 2b accelerated inactivation kinetics which 
also led to slower activation compared to 2a and 2e [100]. 
Taken together, single-channel measurements could reveal further insides into gating 
parameters of the investigated channel complexes. Previous studies could also show effects 
of the different  subunit isoforms on single channel gating, namely open probability [79] 
and single-channel activity [126].  
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Linking this functional analysis to the expression profiling of LTCC subunits, a possible 
mechanism for fine-tuning would arise for VSMCs to modulate channel function by 
complex formation of different  subunits and CaV1.2 splice variants.  
During atherosclerosis, VSMCs switch from a contractile phenotype to a synthetic, i.e. non-
contractile and proliferative phenotype. L-type calcium channel play a major role in Ca2+ 
homeostasis and are important effectors in VSMC excitation-contraction coupling as well as 
for excitation-transcription coupling. Studies could show that Ca2+ entry through LTCC are 
associated with activation of the smooth muscle differentiation marker genes SM-actin 
and SM-myosin heavy chain (SM-MHC) [44, 127]. Functional remodeling of VSMCs during 
dedifferentiation implicates down-regulation of functional L-type calcium channels - a 
decreased ICa2+ as well as a decreased expression of CaV1.2 was shown in cultured 
dedifferentiated rat aortic A7r5 cells [44]. This was additionally shown in primary, 
proliferative VSMCs from the neointima of rat aorta [128]. In human cultured cells from 
saphenous vein, a re-differentiation of VSMCs - indicated by an increase of -actin - was 
linked to increased intracellular Ca2+ and chemotaxis mediated by CaV1.2 [45]. Taking this as 
a background, our functional data reveal that the combination of the predominant 
subunits, 2d and 3a, with the exon 22-containing CaV1.2 would mirror a non-contractile 
and proliferative VSMC phenotyp with reduced function of LTCCs. Furthermore, the 
observed secondary decrease of LTCC subunit expression on mRNA level is consistent with 
observed down-regulation of LTCC expression in primary and cultured rat aortic cells. 
The differential effect of the  subunit splice variants on the two splice variants of CaV1.2 
only differing by exon 21/22 cannot be explained by known structure-function relationships. 
The alternative-spliced exon 21/22 encodes for the second transmembrane helix of domain 
III and the linker between IIIS1 and IIIS2 of CaV1.2.  No subunit interaction-site is described 
for this region of the pore-forming subunit. Furthermore, this region is not known to be an 
important area for specific channel functions up to date [55].  On the other hand, the 
mutually exclusive exons 21 and 22 are known to modify sensitivity to DHP as revealed by 
inhibition of whole-cell currents - although detected binding sites for DHP are located in the 
IS6, IIIS5, IIIS6 and IVS6 transmembrane regions of CaV1.2 [62, 63, 65, 129, 130]. Our data 
may hint to additional unknown functions of the transmembrane helix of domain III and 
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the linker between IIIS1 and IIIS2 which seem to account for the mutual dependence of pore 
splice variants and β-subunit isoforms. 
Taken together,  subunits modulate L-type calcium currents in an isoform- and splice 
variant-specific manner. This study could show that in addition to the differential splicing 
of CaV1.2, specific regulation of  subunits represents another important determinant of 
CaV1.2 remodeling in VSMC. This is suggesting a new possible regulatory mechanism for 
VSMC in health and disease.  
4.4. Conclusion and outlook 
Taken together, the data described in this study demonstrates the functional relevance of 
the splice shift of Cav1.2 exon 21/22 in the context of the different  subunit isoforms (1, 2, 
3) in recombinant human and murine channels. The 2 isoform in human arterial tissue 
and additionally 3 in murine aortic tissue are the predominant  isoforms expressed on 
mRNA level. Exon 21 as well as exon 22 is found in human and murine arterial tissue. There 
is no qualitative switch in human atherosclerotic tissue of LTCC subunits observed in this 
study. Additionally, no switch of LTCC subunits is observed in murine atherosclerosis. 
However, atherosclerosis is linked to a differential expression level of Cav1.2 and  subunit 
isoforms. This indicates complex stage-dependent changes in atherosclerosis which likely 
explain variability found in human samples and possibly causes functional remodeling. The 
ability of CaV1.2, containing either exon 21 or exon 22, to couple with either 2 or 3 could 
provide a mechanism for fine-tuning VSMC function.  
This work was not designed to elucidate why there are different effects on current density 
of the channel complexes containing CaV1.2ex21 or CaV1.2ex22 in combination with different  
subunits. Single-channel analysis would be necessary to gain further insights into single 
channel gating of the prevailing murine channel complexes. Possible occurrence of 
discrepancies between whole-cell and single-channel currents may suggest additional 
effects of β-subunits on membrane targeting. Therefore channel subunits can be examined 
by confocal fluorescence microscopy. Imaging of the surface expression of, e.g., 
hemagglutinin (HA)-tagged CaV1.2 splice variants could reveal potential variations in the 
membrane localization in combination with different  subunits. Immunoluminescence 
could be compared between permeabilized and non-permeabilized cells which would allow 
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to quantify the relative proportion of Cav1.2 channels that are inserted into the plasma 
membrane [85]. Additionally immunohistochemistry with specific antibodies against the 
CaV1.2 pore forming subunit and against specific markers for inner cell structure, like the 
endoplasmatic reticulum or the golgi apparatus, can display distinct localization of the 
CaV1.2 coexpressed with the different  subunits and 2-1. 
The differential effect of  subunits on the two splice variants of CaV1.2 only differing by 
exon 21/22 cannot be explained by structure-function relationships so fare. Further analysis 
of this region within the pore-forming subunit including structure-function analysis with 
the help of deletion-mutants investigated via patch clamp electrophysiology could reveal 
further details for the understanding of structure-function relationships. 
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5. Summary 
Cardiovascular voltage-gated L-type calcium channels (LTCCs) are heteromeric protein 
complexes consisting of a pore-forming CaV1.2 subunit, an intracellular subunit and a 2 
subunit complex. The function of voltage-gated calcium channels has major impact on the 
function and contractility of vascular smooth muscle cells (VSMCs). The influx of external 
calcium (Ca2+) regulates intracellular free Ca2+ - thereby arterial tone - and is important for 
additional biological processes inside the cell. An increase of cytosolic intracellular Ca2+ is 
for example needed for proliferation of VSMCs.  
It has been reported that in human atherosclerosis, vascular smooth muscle Cav1.2 isoforms 
containing exon 21 are replaced by one single isoform containing the alternative exon 22. 
Previous functional studies in our group reveal that this splice shift has major effects on 
LTCC function, depending on the β subunit co-expressed: a β3 subunit together with 
Cav1.2exon 21 led to markedly reduced current density compared to Cav1.2exon 22. Coexpression 
of a β2 subunit with either Cav1.2exon 21 or Cav1.2exon 22 had the opposite effect. 
The present work examined the LTCC subunit expression pattern in both human and 
murine atherosclerotic arterial tissues. Samples of human atherosclerotic arteries were 
obtained from patients undergoing carotid or femoral arterial bypass surgery. Human 
vascular smooth muscle tissue was isolated by laser microdissection or the whole arterial 
sample was examined. Mouse aorta was isolated from healthy wildtype and atherosclerotic 
apoE-knockout (-/-) animals. LTCC subunit mRNA expression was quantified by qRT-PCR. 
Furthermore, the electrophysiology of the most abundant murine CaV1.2 channel complexes 
was characterized at whole-cell level. 
In human arterial samples, mRNA of all 4 β subunits, β1-4, is expressed along with Cav1.2.  
The β2 subunit mRNA seemed to be most consistently and predominantly expressed. Both 
exon 21- and exon 22-containing CaV1.2 subunit mRNA isoforms were found in 
atherosclerotic and non-affected tissue. Atherosclerosis was associates with a slight decrease 
of LTCC channel subunits in femoral arterial tissue.  
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In murine aortic tissue, both exon 21- and exon 22 containing CaV1.2 subunit mRNA was 
detected in healthy and diseased tissue. The 2d and 3 subunits are the predominant  
isoforms in arterial tissue. Furthermore, atherosclerosis is associated with a transient 
increase of CaV1.2 channel subunits (2d, 3, CaV1.2) followed by a strong decrease in later 
stages of atherosclerosis.  
In recombinant murine channels the combination with different  subunit isoforms 
uncovers the functional relevance of the exon 21-exon 22 structural diversity. The channel 
complexes containing 2d and 3 lead to a significantly reduced current density together 
with the exon 22 containing CaV1.2. In contrast channel complexes containing 2b cause an 
increased current density together with a shift of peak current density towards more 
hyperpolarizing potentials. 
Taken together, the data described in this study demonstrate the functional relevance of the 
splice shift of Cav1.2 exon 21/22 in the context of the different  subunit isoforms (1, 2, 3) 
in recombinant human and murine channels. The 2 isoform in human arterial tissue and 
additionally 3 in murine aortic tissue are the predominant  isoforms expressed on mRNA 
level. In murine aorta, 2d is the predominant 2 splice variant. Exon 21 as well as exon 22 
are found in human and murine arterial tissue. This study do not hint at a clear cut 
“atherosclerotic” change of expression pattern, but indicates that the exact stage of 
atherosclerosis is a critical determinant of pathological LTCC remodelling.  
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